Document:

ENUMERAL
BIOMEDICAL HOLDINGS, INC.

2014 Equity
Incentive Plan

July 31,
2014

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	I.	ESTABLISHMENT, OBJECTIVES AND DURATION	2
	 	 	 
	II.	DEFINITIONS	2
	 	 	 
	III.	ADMINISTRATION	7
	 	 	 
	IV.	SHARES SUBJECT TO THE PLAN AND MAXIMUM AWARDS	7
	 	 	 
	V.	ELIGIBILITY AND PARTICIPATION	10
	 	 	 
	VI.	STOCK OPTIONS	10
	 	 	 
	VII.	STOCK APPRECIATION RIGHTS	12
	 	 	 
	VIII.	RESTRICTED STOCK	13
	 	 	 
	IX.	RESTRICTED STOCK UNITS	17
	 	 	 
	X.	PERFORMANCE UNITS AND PERFORMANCE SHARES	18
	 	 	 
	XI.	PERFORMANCE MEASURES	19
	 	 	 
	XII.	BENEFICIARY DESIGNATION	20
	 	 	 
	XIII.	DEFERRALS	20
	 	 	 
	XIV.	RIGHTS OF PARTICIPANTS	20
	 	 	 
	XV.	AMENDMENT, MODIFICATION, TERMINATION AND ADJUSTMENTS	20
	 	 	 
	XVI.	PAYMENT OF PLAN AWARDS AND CONDITIONS THEREON	22
	 	 	 
	XVII.	CHANGE IN CONTROL	22
	 	 	 
	XVIII.	TAX PROVISIONS	22
	 	 	 
	XIX.	INDEMNIFICATION	23
	 	 	 
	XX.	SUCCESSORS	24
	 	 	 
	XXI.	LEGAL CONSTRUCTION	24

 

    	i

    	 

    

 

ENUMERAL
BIOMEDICAL HOLDINGS, INC.

2014 Equity Incentive Plan

July 31, 2014

 

I.           ESTABLISHMENT,
OBJECTIVES AND DURATION

 

A.           ESTABLISHMENT
OF THE PLAN. Enumeral Biomedical Holdings, Inc., a Delaware corporation (hereinafter referred to as the “Company”),
hereby adopts an incentive compensation plan known as the “Enumeral Biomedical Holdings, Inc. 2014 Equity Incentive Plan”
(hereinafter referred to as the “Plan”), as set forth in this document. The Plan permits the grant of Nonqualified
Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares
and Performance Units.

 

Subject to approval by
the Company’s stockholders, the Plan shall become effective as of July 31, 2014 (the “Effective Date”). The Plan
shall remain in effect as provided in Section I.C hereof.

 

B.           OBJECTIVES
OF THE PLAN. The objectives of the Plan are to optimize the profitability and growth of the Company through incentives which are
consistent with the Company’s goals and which link the personal interests of Participants to those of the Company’s
stockholders; to provide Participants with an incentive for excellence in individual performance; and to promote teamwork among
Participants.

 

It is also intended with
respect to the Non-Employee Directors of the Company that the Compensation Committee be able to choose from among Awards of Non-Qualified
Stock Options, Stock Appreciation Rights, Restricted Stock and RSUs which will (a) permit Non-Employee Directors to increase their
ownership and proprietary interest in the Company and enhance their identification with the interests of the Company’s stockholders,
(b) provide a means of compensating Non-Employee Directors that will help attract qualified candidates to serve as Non-Employee
Directors, and (c) induce incumbent Non-Employee Directors to continue to serve if the Board desires that they remain on the Board.

 

C.           DURATION
OF THE PLAN. The Plan shall commence on the Effective Date and shall remain in effect, subject to the right of the Board of Directors
to amend or terminate the Plan at any time pursuant to Article XV hereof, until all Shares subject to it shall have been purchased
or acquired according to the Plan’s provisions. However, in no event may an Award be granted under the Plan on or after July
29, 2024.

 

II.          DEFINITIONS

 

Whenever used in the Plan,
the following terms shall have the meanings set forth below, and when the meaning is intended, the initial letter of the word shall
be capitalized:

 

A.           “AFFILIATE”
shall have the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations of the Exchange Act.

 

    	 

    	 

    

 

B.           “AWARD”
means, individually or collectively, a grant under this Plan of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation
Rights, Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units.

 

C.           “AWARD
AGREEMENT” means an agreement entered into by the Company and each Participant setting forth the terms and provisions applicable
to Awards granted under this Plan.

 

D.           “BENEFICIAL
OWNER” or “BENEFICIAL OWNERSHIP” shall have the meaning ascribed to such term in Rule 13d-3 of the General Rules
and Regulations under the Exchange Act.

 

E.           “BOARD”
or “BOARD OF DIRECTORS” means the Board of Directors of the Company.

 

F.           “CHANGE
IN CONTROL” shall be deemed to have occurred as of the first day that any one or more of the following conditions shall have
been satisfied:

 

1.           the
“Beneficial Ownership” of securities as defined in Rule 13d-3 under the Exchange Act representing more than thirty-three
percent (33%) of the combined voting power of the Company is acquired by any “person” as defined in Section 3(a)(9)
of the Exchange Act (other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of
the Company, or any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions
as their ownership of stock of the Company); or

 

2.           the
consummation of a definitive agreement to merge or consolidate the Company with or into another corporation or to sell or otherwise
dispose of all or substantially all of its assets, or adopt a plan of liquidation; or

 

3.           during
any period of three consecutive years, individuals who at the beginning of such period were members of the Board cease for any
reason to constitute at least a majority thereof (unless the election, or the nomination for election by the Company’s stockholders,
of each new director was approved by a vote of at least a majority of the directors then still in office who were directors at
the beginning of such period or whose election or nomination was previously so approved).

 

Notwithstanding the foregoing, with
respect to any Award subject to Code Section 409A, a “Change in Control” of the Company is deemed to have occurred
as of the first day that any one or more of the following conditions shall have been satisfied:

 

4.           Change
in Ownership: A change in ownership of the Company occurs on the date that any one person, or more than one person acting as
a group, acquires ownership of stock of the Company that, together with stock held by such person or group, constitutes more than
fifty percent (50%) of the total fair market value or total voting power of the stock of the Company, excluding the acquisition
of additional stock by a person or more than one person acting as a group who is considered to own more than fifty percent (50%)
of the total fair market value or total voting power of the stock of the Company.

 

    	3

    	 

    

 

5.           Change
in Effective Control: A change in effective control of the Company occurs only on either of the following dates:

 

a.           The
date any one person, or more than one person acting as a group, acquires (or has acquired during the twelve (12) month period ending
in the date of the most recent acquisition by such person or persons) ownership of stock of the Company possessing 30% or more
of the total voting power of the stock of the Company; or

 

b.           The
date a majority of the members of the Board is replaced during any (12) month period by directors whose appointment or election
is not endorsed by a majority of the members of the board of directors before the date of the appointment or election; provided
that this paragraph (b) shall apply only to the company for which no other corporation is a majority shareholder.

 

6.           Change
in Ownership of Substantial Assets: A change in the ownership of a substantial portion of the Company’s assets occurs
on the date that any one person, or more than one person acting as a group, acquires (or has acquired during the twelve (12) month
period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross
fair market value equal to or more than forty percent (40%) of the total gross fair market value of the assets of the Company,
or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.

 

It is the intent that this definition
be construed to satisfy the definition of “Change of Control” as defined under Internal Revenue Code Section 409A and
the applicable Treasury Regulations, as amended from time to time.

 

G.          “CODE”
means the Internal Revenue Code of 1986, as amended from time to time.

 

H.          “COMMITTEE”
means any committee appointed by the Board to administer the Plan, as specified in Article III herein.

 

I.           “COMPANY”
means Enumeral Biomedical Holdings, Inc., a Delaware corporation, including any and all Subsidiaries, and any successor thereto
as provided in Article XX herein.

 

J.           “COVERED
EMPLOYEE” means a Participant who, as of the date of vesting and/or payout of an Award, as applicable, is one of the group
of “covered employees,” as defined in Code Section 162(m) and the regulations promulgated under Code Section 162(m),
or any successor statute.

 

    	4

    	 

    

 

K.          “DIRECTOR”
means any individual who is a member of the Board of Directors of the Company or any Subsidiary; provided, however, that any Director
who is employed by the Company shall be considered an Employee under the Plan.

 

L.           “DISABILITY”
with respect to any Award, a Participant shall be considered Disabled if the Participant is considered “disabled” under
the Company’s long-term disability plan then in effect, or if none, then if the Participant qualifies to receive disability
payments under the federal Social Security Act.

 

M.          “EFFECTIVE
DATE” shall mean July 31, 2014.

 

N.           “EMPLOYEE”
means any full-time, active employee of the Company or its Subsidiaries. Directors who are not employed by the Company shall not
be considered Employees under this Plan.

 

O.           “EXCHANGE
ACT” means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.

 

P.           “FAIR
MARKET VALUE” shall be determined on the basis of the closing sale price at which Shares have been sold on the principal
securities exchange on which the Shares are traded or, if there is no such sale on the relevant date, then on the last previous
day on which there was such a sale.

 

Q.           “FREESTANDING
SAR” means an SAR that is granted independently of any Options, as described in Article VII herein.

 

R.           “INCENTIVE
STOCK OPTION” or “ISO” means an option to purchase Shares granted under Article VI herein and which is designated
as an Incentive Stock Option and which is intended to meet the requirements of Code Section 422.

 

S.           “INSIDER”
shall mean an individual who is, on the relevant date, an officer, director or more than ten percent (10%) Beneficial Owner of
any class of the Company’s equity securities that is registered pursuant to Section 12 of the Exchange Act, all as defined
under Section 16 of the Exchange Act.

 

T.           “NON-EMPLOYEE
DIRECTOR” shall mean a Director who is not also an Employee.

 

U.           “NON-QUALIFIED
STOCK OPTION” or “NQSO” means an option to purchase Shares granted under Article VI herein and which is not intended
to meet the requirements of Code Section 422.

 

V.          “OPTION”
means an Incentive Stock Option or a Nonqualified Stock Option, as described in Article VI herein.

 

    	5

    	 

    

 

W.         “OPTION PRICE”
means the price at which a Share may be purchased by a Participant pursuant to an Option.

 

X.           “PARTICIPANT”
means: (1) an Employee or consultant who has been selected to receive an Award or who has an outstanding Award granted under the
Plan; or (2) a Non-Employee Director who has been selected to receive an Award other than an Incentive Stock Option, Performance
Share or Performance Unit or who has an outstanding Award other than an Incentive Stock Option, Performance Share or Performance
Unit granted under the Plan.

 

Y.           “PERFORMANCE-BASED
EXCEPTION” means the performance-based exception from the tax deductibility limitations of Code Section 162(m).

 

Z.           “PERFORMANCE
SHARE” means an Award granted to a Participant (other than a Non-Employee Director), as described in Article X herein, that
shall have an initial value equal to the Fair Market Value of a Share on the date of grant.

 

AA.       “PERFORMANCE
UNIT” means an Award granted to a Participant (other than a Non-Employee Director), as described in Article X herein, that
shall have an initial value that is established by the Committee on the date of grant.

 

BB.         “PERIOD
OF RESTRICTION” means the period during which the transfer of Shares of Restricted Stock or Restricted Stock Units is limited
in some way (based on the passage of time, the achievement of performance goals or upon the occurrence of other events as determined
by the Committee, at its discretion, as specified in the Award Agreement), and the Shares are subject to a substantial risk of
forfeiture, as provided in Article VIII and Article IX herein.

 

CC.          “PERSON”
shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof,
including a “group” as defined in Section 13(d) thereof.

 

DD.          “RESTRICTED
STOCK” means an Award granted to a Participant pursuant to Article VIII herein.

 

EE.          “RESTRICTED
STOCK UNIT” or “RSU” means an award granted to a Participant pursuant to Article IX herein.

 

FF.          “SEPARATION
FROM SERVICE” means a termination of employment or other separation from service as described in Code Section 409A and the
regulations thereunder.

 

GG.          “SHARES”
means the shares of common stock of the Company.

 

HH.          “SPECIFIED
EMPLOYEE”means, with respect to the Company or any of its Subsidiaries, and determined as of the date of an individual’s
separation from service from the Company (1) any officer during the prior twelve (12) month period with annual compensation in
excess of $170,000 (as adjusted from time to time under the Code), (2) a 5-percent owner of the Company’s outstanding equity
stock during the prior twelve (12) month period or (3) a 1-percent owner of the Company’s outstanding equity stock during
the prior (12) month period with annual compensation in excess of $150,000 (as adjusted from time under Code), provided that the
Company or any of its Subsidiaries is publicly-traded within the meaning of Code Section 409A on the date of determination.

 

    	6

    	 

    

 

II.          “STOCK
APPRECIATION RIGHT” or “SAR” means an Award, granted alone or, in connection with a related Option, designated
as an SAR, pursuant to the terms of Article VII herein.

 

JJ.          “SUBSIDIARY”
means any corporation, partnership, joint venture or other entity in which the Company has a majority voting interest (including
all divisions, affiliates and related entities).

 

KK.          “TANDEM
SAR” means an SAR that is granted in connection with a related Option pursuant to Article VII herein, the exercise of which
shall require forfeiture of the right to purchase a Share under the related Option (and when a Share is purchased under the Option,
the Tandem SAR shall similarly be canceled).

 

III.         ADMINISTRATION

 

A.          THE
COMMITTEE. The Plan shall be administered by the Committee of the Board consisting of not less than two Directors who meet the
“Non-Employee Director” requirements of Rule 16b-3 promulgated by the Securities and Exchange Commission under the
Exchange Act, the “Independent Director” requirements of NYSE MKT Rule 803(a), and the outside director requirements
of Code Section 162(m), or by any other committee appointed by the Board, provided the members of such committee meet such requirements.

 

B.           AUTHORITY
OF THE COMMITTEE. Except as limited by law or by the Articles of Incorporation or Bylaws of the Company, and subject to the provisions
herein, the Committee shall have full power to select Employees and Non-Employee Directors who shall participate in the Plan; determine
the sizes and types of Awards; determine the terms and conditions of Awards in a manner consistent with the Plan; construe and
interpret the Plan and any agreement or instrument entered into under the Plan; establish or amend rules and regulations for the
Plan’s administration; and (subject to the provisions of Article XV herein) amend the terms and conditions of any outstanding
Award to the extent such terms and conditions are within the discretion of the Committee as provided in the Plan. Further, the
Committee is empowered hereby to make all other determinations which may be necessary or advisable for the administration of the
Plan. As permitted by law, the Committee may delegate its authority as identified herein.

 

C.           DECISIONS
BINDING. All determinations and decisions made by the Committee pursuant to the provisions of the Plan and all related orders and
resolutions of the Board shall be final, conclusive and binding on all persons, including the Company, its stockholders, Directors,
Employees, Participants and their estates and beneficiaries.

 

IV.         SHARES
SUBJECT TO THE PLAN AND MAXIMUM AWARDS

 

A.           NUMBER
OF SHARES AVAILABLE FOR GRANTS. Subject to Sections IV.B and IV.C herein, the maximum number of Shares with respect to which Awards
may be granted to Participants under the Plan shall be Eight Million One-Hundred Thousand (8,100,000). Shares issued under the
Plan may be either authorized but unissued Shares, treasury Shares or any combination thereof.

 

    	7

    	 

    

 

Unless and until the Committee
determines that an Award to a Covered Employee is not designed to comply with the Performance-Based Exception, the following rules
shall apply to grants of Awards to Covered Employees under the Plan, subject to Sections IV.B and IV.C.

 

1.           STOCK
OPTIONS: The maximum aggregate number of Shares that may be subject to Stock Options granted in any one fiscal year to any one
Participant shall be two hundred thousand (200,000).

 

2.           SARs:
The maximum aggregate number of Shares that may be granted in the form of SARs granted in any one fiscal year to any one Participant
shall be two hundred thousand (200,000).

 

3.           RESTRICTED
STOCK: The maximum aggregate grant with respect to Awards of Restricted Stock which are granted in any one fiscal year to any one
Participant shall be one hundred thousand (100,000) Shares.

 

4.           RESTRICTED
STOCK UNITS: The maximum aggregate payment (determined as of the date of grant) with respect to Awards of RSUs granted in any one
fiscal year to any one Participant shall be equal to the Fair Market Value of one hundred thousand (100,000) Shares; provided,
however, that the maximum aggregate grant of Restricted Stock and RSUs for any one fiscal year shall be coordinated so that in
no event shall any one Participant be awarded more than the Fair Market Value of one hundred thousand (100,000) Shares taking into
account all such grants.

 

5.           PERFORMANCE
SHARES: The maximum aggregate payout (determined as of the event of the applicable performance period) with respect to Awards of
Performance Shares which are granted in any one fiscal year to any one Participant shall be equal to the Fair Market Value of one
hundred fifty thousand (150,000) Shares.

 

6.           PERFORMANCE
UNITS: The maximum aggregate payout (determined as of the end of the applicable performance period) with respect to Awards of Performance
Units which are granted in any one fiscal year to any one Participant shall be equal to one million five hundred thousand dollars
($1,500,000).

 

B.           ADJUSTMENTS
FOR AWARDS AND PAYOUTS. Unless determined otherwise by the Committee, the following Awards and payouts will reduce, on a one-for-one
basis, the number of Shares available for issuance under the Plan:

 

1.          An
Award of an Option;

 

2.          An
Award of a SAR;

 

    	8

    	 

    

 

3.          An
Award of Restricted Stock;

 

4.          A
payout of a Performance Share Award in Shares; and

 

5.          A
payout of a Performance Units Award in Shares.

 

Unless determined otherwise
by the Committee, unless a Participant has received a benefit of ownership such as dividend or voting rights with respect to the
Award, the following transactions will restore, on a one-for-one basis, the number of Shares available for issuance under the Plan:

 

1.           A
payout of a SAR or a Tandem SAR in cash;

 

2.           A
cancellation, termination, expiration, forfeiture or lapse for any reason (with the exception of the termination of a Tandem SAR
upon exercise of the related Options, or the termination of a related Option upon exercise of the corresponding Tandem SAR) of
any Award payable in Shares;

 

3.           Shares
tendered in payment of the exercise price of an Option;

 

4.           Shares
withheld for payment of federal, state or local taxes;

 

5.           Shares
repurchased by the Company with proceeds collected in connection with the exercise of outstanding Options; and

 

6.           The
net Shares issued in connection with the exercise of SARs (as opposed to the full number of Shares underlying the exercised portion
of the SAR).

 

C.           ADJUSTMENTS
IN AUTHORIZED SHARES. In the event of any change in corporate capitalization such as a stock split or stock dividend, or a corporate
transaction such as any merger, consolidation, separation, including a spin-off, or other distribution of stock or property of
the Company, any reorganization (whether or not such reorganization comes within the definition of such term in Code Section 368)
or any partial or complete liquidation of the Company, such adjustment shall be made in the number and class of Shares which are
reserved and may be delivered under Section IV.A, in the number and class of and/or price of Shares subject to outstanding Awards
granted under the Plan, and in the Award limits set forth in subsections IV.A.1 through IV.A.6, inclusive as may be determined
to be appropriate and equitable by the Committee, in its sole discretion, to prevent dilution or enlargement of rights; provided,
however, that the number of Shares subject to any Award shall always be a whole number.

 

    	9

    	 

    

 

		V.	ELIGIBILITY AND PARTICIPATION

 

A.           ELIGIBILITY.
Persons eligible to participate in this Plan include officers and certain key salaried Employees of the Company with potential
to contribute to the success of the Company or its Subsidiaries, including Employees who are members of the Board. Notwithstanding
the foregoing, Non-Employee Directors of the Company or consultants shall be eligible to participate in the Plan with respect to
Awards of Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock and RSUs, as specified in Article VI, Article
VII, Article VIII and Article IX. Except as otherwise specifically provided in this Plan, the Committee shall determine the terms
and conditions of any such Awards to Non-Employee Directors, including the terms and conditions which shall apply upon a termination
of the Non-Employee Director’s service as a member of the Board, and shall have full power and authority in its discretion
to administer such Awards, subject to the terms of the Plan and applicable law.

 

B.           ACTUAL
PARTICIPATION. Subject to the provisions of the Plan, the Committee may, from time to time, select in its sole and broad discretion,
upon or without the recommendation of officers of the Company, from all eligible Employees those to whom Awards shall be granted,
and shall determine the nature and amount of each Award.

 

VI.         STOCK
OPTIONS

 

A.           GRANT
OF OPTIONS. Subject to the terms and provisions of the Plan, Options may be granted to Participants in such number, and upon such
terms, and at any time and from time to time as shall be determined by the Committee. For purposes of this Article VI, with respect
to NQSOs only, the term “Participant” shall include Non-Employee Directors and consultants of the Company.

 

B.           AWARD
AGREEMENT. Each Option grant shall be evidenced by an Award Agreement that shall specify the Option Price, the duration of the
Option, the number of Shares to which the Option pertains, and such other provisions as the Committee shall determine. The Award
Agreement also shall specify whether the Option is intended to be an ISO within the meaning of Code Section 422, or an NQSO, whose
grant is intended not to fall under the provisions of Code Section 422.

 

C.           OPTION
PRICE. The Option Price for each grant of an Option under this Plan shall be at least equal to one hundred percent (100%) of the
Fair Market Value of a Share on the date the Option is granted. Notwithstanding the foregoing, no ISO shall be granted to any person
who, immediately prior to the grant, owns stock possessing more than ten percent (10%) of the total combined voting power of all
classes of stock of the Company, unless the Option Price is at least one hundred ten percent (110%) of the Fair Market Value of
a Share on the date of grant of the Option.

 

D.           DURATION
OF OPTIONS. Each Option granted to a Participant shall expire at such time as the Committee shall determine at the time of grant;
provided, however, that no Option shall be exercisable later than the tenth (10th) anniversary following the date of
its grant and provided further that no Option that is an ISO shall be exercisable later than the fifth (5th) anniversary
following the date of its grant to a Participant, who at the time of such grant owns stock possessing more than ten percent (10%)
of the total combined voting power of all classes of stock of the Company.

 

E.           EXERCISE
OF OPTIONS. Options granted under this Article VI shall be exercisable at such times and be subject to such restrictions and conditions
as the Committee shall in each instance approve, which need not be the same for each grant or for each Participant.

 

    	10

    	 

    

 

F.           PAYMENT.
Options granted under this Article VI shall be exercised by the delivery of a written notice of exercise to the Company, setting
forth the number of Shares with respect to which the Option is to be exercised, accompanied by full payment for the Shares.

 

The Option Price upon exercise
of any Option shall be payable to the Company in full either: (a) in cash or its equivalent; or (b) by tendering previously acquired
Shares having an aggregate Fair Market Value at the time of exercise equal to the total Option Price (provided that the Shares
which are tendered must have been held by the Participant for at least six months prior to their tender to satisfy the Option Price);
or (c) by a combination of (a) and (b).

 

The Committee, in its discretion,
may also (a) allow cashless exercise as permitted under Federal Reserve Board’s Regulation T, subject to applicable securities
law restrictions, (b) cashless exercise by the Participant by the Company’s withholding of Shares issuable upon exercise
of an Option, or (c) by any other means which the Committee determines to be consistent with the Plan’s purpose and applicable
law.

 

Subject to any governing
rules or regulations, as soon as practicable after receipt of a written notification of exercise and full payment, the Company
shall deliver to the Participant, in the Participant’s name, Share certificates in an appropriate amount based upon the number
of Shares purchased under the Option(s).

 

G.           RESTRICTIONS
ON SHARE TRANSFERABILITY. The Committee may impose such restrictions on any Shares acquired pursuant to the exercise of an Option
granted under this Article VI as it may deem advisable, including, without limitation, restrictions under applicable federal securities
laws, under the requirements of any stock exchange or market upon which such Shares are then listed and/or traded, and under any
blue sky or state securities laws applicable to such Shares.

 

H.           TERMINATION
OF EMPLOYMENT BY A PARTICIPANT WHO IS AN EMPLOYEE. With respect to a Participant who is an Employee, each Option Award Agreement
shall set forth the extent to which the Participant shall have the right to exercise the Option following termination of the Participant’s
employment with the Company, with the exception of a termination of employment after a Change in Control, which is controlled by
Article XVII. Such provisions shall be determined in the sole discretion of the Committee but shall conform to the limitations
established in Section VI.D, shall be included in the Award Agreement entered into with each Participant, need not be uniform among
all Options issued pursuant to this Article VI, and may reflect distinctions based on the reasons for termination of employment.

 

I.           NONTRANSFERABILITY
OF OPTIONS.

 

1.           INCENTIVE
STOCK OPTIONS. No ISO granted under the Plan may be sold, transferred, pledged, assigned or otherwise alienated or hypothecated,
other than by will or by the laws of descent and distribution. Further, all ISOs granted to a Participant under the Plan shall
be exercisable during his or her lifetime only by such Participant or the Participant’s legal representative (to the extent
permitted under Code Section 422).

 

    	11

    	 

    

 

2.           NONQUALIFIED
STOCK OPTIONS. No NQSO granted under this Article VI may be sold, transferred, pledged, assigned or otherwise alienated or hypothecated,
other than by will or by the laws of descent and distribution. Further, except as otherwise provided in a Participant’s Award
Agreement, all NQSOs granted to a Participant under this Article VI shall be exercisable during his or her lifetime only by such
Participant or the Participant’s legal representative.

 

VII.        STOCK
APPRECIATION RIGHTS

 

A.           GRANT
OF SARS. Subject to the terms and conditions of the Plan, SARs may be granted to Participants at any time and from time to time
as shall be determined by the Committee. The Committee may grant Freestanding SARs, Tandem SARs or any combination of these forms
of SAR. For purposes of this Article VII, the term “Participant” shall include Non-Employee Directors of the Company
and consultants; provided, however, that a Tandem SAR may not be granted to a Non-Employee Director or consultant unless the related
Option is a NQSO.

 

The Committee shall have
complete discretion in determining the number of SARs granted to each Participant (subject to Article IV herein) and, consistent
with the provisions of the Plan, in determining the terms and conditions pertaining to such SARs.

 

The grant price of a Freestanding
SAR shall equal the Fair Market Value of a Share on the date of grant of the SAR. The grant price of Tandem SARs shall equal the
Option Price of the related Option.

 

B.           EXERCISE
OF TANDEM SARS. Tandem SARs may be exercised for all or part of the Shares subject to the related Option upon the surrender of
the right to exercise the equivalent portion of the related Option. A Tandem SAR may be exercised only with respect to the Shares
for which its related Option is then exercisable.

 

Notwithstanding any other
provision of this Plan to the contrary, with respect to a Tandem SAR granted to an Employee in connection with an ISO: (i) the
Tandem SAR will expire no later than the expiration of the underlying ISO; (ii) the value of the payout with respect to the Tandem
SAR may be for no more than one hundred percent (100%) of the difference between the Option Price of the underlying ISO and the
Fair Market Value of the Shares subject to the underlying ISO at the time the Tandem SAR is exercised; and (iii) the Tandem SAR
may be exercised only when the Fair Market Value of the Shares subject to the ISO exceeds the Option Price of the ISO.

 

C.           EXERCISE
OF FREESTANDING SARS. Freestanding SARs may be exercised upon whatever terms and conditions the Committee, in its sole discretion,
imposes upon them.

 

D.           SAR
AGREEMENT. Each SAR grant shall be evidenced by an Award Agreement that shall specify the grant price, the term of the SAR, and
such other provisions as the Committee may determine.

 

    	12

    	 

    

 

E.           TERM
OF SARS. The term of an SAR granted under the Plan shall be determined by the Committee, in its sole discretion; provided, however,
that such term shall not exceed ten (10) years.

 

F.           PAYMENT
OF SAR AMOUNT. Upon exercise of an SAR, a Participant shall be entitled to receive payment from the Company in an amount determined
by multiplying:

 

1.           the
difference between the Fair Market Value of a Share on the date of exercise over the grant price; by

 

2.           the
number of Shares with respect to which the SAR is exercised.

 

At the discretion of the
Committee, the payment upon SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The Committee’s
determination regarding the form of SAR payout shall be set forth in the Award Agreement pertaining to the grant of the SAR.

 

G.           TERMINATION
OF EMPLOYMENT BY A PARTICIPANT WHO IS AN EMPLOYEE. With respect to a Participant who is an Employee, each SAR Award Agreement shall
set forth the extent to which the Participant shall have the right to exercise the SAR following termination of the Participant’s
employment with the Company and/or its Subsidiaries, with the exception of a termination of employment that occurs after a Change
in Control, which is controlled by Article XVII. Such provisions shall be determined in the sole discretion of the Committee, shall
be included in the Award Agreement entered into with Participants, need not be uniform among all SARs issued pursuant to the Plan
and may reflect distinctions based on the reasons for termination of employment.

 

H.           NONTRANSFERABILITY
OF SARS. No SAR granted under the Plan may be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other
than by will or by the laws of descent and distribution. Further, except as otherwise provided in a Participant’s Award Agreement,
all SARs granted to a Participant under the Plan shall be exercisable during his or her lifetime only by such Participant or the
Participant’s legal representative.

 

VIII.       RESTRICTED
STOCK

 

A.           GRANT
OF RESTRICTED STOCK. Subject to the terms and provisions of the Plan, the Committee, at any time and from time to time, may grant
Shares of Restricted Stock to Participants in such amounts as the Committee shall determine. For purposes of this Article VIII,
the term “Participant” shall include Non-Employee Directors of the Company and consultants.

 

B.           RESTRICTED
STOCK AGREEMENT. Each Restricted Stock grant shall be evidenced by a Restricted Stock Award Agreement that shall specify the Period(s)
of Restriction, the number of Shares of Restricted Stock granted and such other provisions as the Committee shall determine.

 

    	13

    	 

    

 

C.           NONTRANSFERABILITY.
Except as provided in this Article VIII and subject to federal securities laws, the Shares of Restricted Stock granted under the
Plan may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated until the end of the applicable Period
of Restriction established by the Committee and specified in the Restricted Stock Award Agreement, or upon earlier satisfaction
of any other conditions, as specified by the Committee in its sole discretion and as set forth in the Restricted Stock Award Agreement.
All rights with respect to the Restricted Stock granted to a Participant under the Plan shall be available during his or her lifetime
only to such Participant or the Participant’s legal representative for the Period of Restriction.

 

D.           OTHER
RESTRICTIONS. Subject to Article XI herein, the Committee may impose such other conditions and/or restrictions on any Shares of
Restricted Stock granted pursuant to the Plan as it may deem advisable including, without limitation, a requirement that Participants
pay a stipulated purchase price for each Share of Restricted Stock, restrictions based upon the achievement of specific performance
goals (Company-wide, divisional and/or individual), time-based restrictions on vesting following the attainment of the performance
goals and/or restrictions under applicable federal or state securities laws.

 

The Company may retain
the certificates representing Shares of Restricted Stock in the Company’s possession until such time as all conditions and/or
restrictions applicable to such Shares have been satisfied.

 

Except as otherwise provided
in this Article VIII and subject to Federal securities laws, Shares of Restricted Stock covered by each Restricted Stock grant
made under the Plan shall become freely transferable by the Participant after the last day of the applicable Period of Restriction.

 

E.           VOTING
RIGHTS. Participants holding Shares of Restricted Stock granted hereunder may be granted the right to exercise full voting rights
with respect to those Shares during the Period of Restriction.

 

F.           DIVIDENDS
AND OTHER DISTRIBUTIONS. During the Period of Restriction, Participants holding Shares of Restricted Stock granted hereunder shall
be credited with regular cash dividends paid with respect to the underlying Shares while they are so held. The Committee may apply
any restrictions to the dividends that the Committee deems appropriate. Without limiting the generality of the preceding sentence,
if the grant or vesting of Restricted Stock granted to a Covered Employee is designed to comply with the requirements of the Performance-Based
Exception, the Committee may apply any restrictions it deems appropriate to the payment of dividends declared with respect to such
Restricted Stock, such that the dividends and/or the Restricted Stock maintain eligibility for the Performance-Based Exception.
Notwithstanding anything to the contrary herein, (i) dividends accrued on Restricted Stock will only be paid if the Restricted
Stock vests; and (ii) for any Award that is governed by Code Section 409A regarding non-qualified deferred compensation, the Committee
shall establish the schedule of any payments of dividends in accordance with the requirements of Code Section 409A or any guidance
promulgated thereunder.

 

    	14

    	 

    

 

G.           TERMINATION
OF EMPLOYMENT BY A PARTICIPANT WHO IS AN EMPLOYEE. With respect to a Participant who is an Employee, each Restricted Stock Award
Agreement shall set forth the extent to which the Participant shall have the right to receive nonvested Restricted Shares following
termination of the Participant’s employment with the Company. Such provisions shall be determined in the sole discretion
of the Committee, shall be included in the Award Agreement entered into with each Participant, need not be uniform among all Shares
of Restricted Stock issued pursuant to the Plan and may reflect distinctions based on the reasons for termination of employment.

 

H.           VESTING
OF RESTRICTED STOCK AWARDS. Unless otherwise provided in the Plan or under an Award Agreement: (1) all Awards of Restricted Stock
that vest based on the passage of time which are granted to a Participant shall vest no more rapidly than pro-rata over a three
(3) year period from the date of grant (the “Time-Based Restricted Stock”); and (2) all Awards of Restricted Stock
that vest based on the achievement of specific measures designed to satisfy the Performance-Based Exception or other performance
measures which are granted to a Participant shall vest no more rapidly than one (1) year from the date of grant (the “Performance-Based
Restricted Stock”); provided, however: (1) up to ten percent (10%) of the Time-Based Restricted Stock Awards, Performance-Based
Restricted Stock Awards, or both, may by designation of the Committee (as reflected in the Restricted Stock Award Agreement), be
subject to a more accelerated time-based vesting schedule or performance-based vesting schedule, as the case may be; and (2) Restricted
Stock Awards which fully vest upon certain termination events as determined by the Committee and specified in the Employee’s
Restricted Stock Award Agreement (or as a result of termination from the Board as a Non-Employee Director pursuant to Section VIII.I.3.f.)
or a Change in Control shall not count as part of this ten percent (10%) pool.

 

I.            ADDITIONAL
PROVISIONS RELATED TO RESTRICTED STOCK AWARDS TO NON-EMPLOYEE DIRECTORS.

 

1.           AWARD
DATES. Effective as of the date specified by the Committee in its sole discretion, each Non-Employee Director will be awarded such
number of Shares of Restricted Stock as determined by the Board, after consideration of the recommendation of the Committee. Non-Employee
Directors may, but need not, be awarded the same number of Shares of Restricted Stock. A Non-Employee Director who is first elected
to the Board on a date subsequent to the date specified by the Committee in its sole discretion will be awarded such number of
Shares of Restricted Stock as of such date of election as determined by the Board, after consideration of the recommendation of
the Committee.

 

2.           DIVIDEND
RIGHTS OF HOLDERS OF RESTRICTED STOCK. Notwithstanding Section VIII.F., upon issuance of a Restricted Stock Agreement, the Non-Employee
Director in whose name the Restricted Stock Agreement is registered will, subject to the provisions of the Plan have the right
to receive cash dividends and other cash distributions thereon.

 

3.           PERIOD
OF RESTRICTION. Restricted Stock will be subject to the restrictions set forth in Section VIII.I.4. and the other provisions of
the Plan during the Period of Restriction commencing on the date as of which the Restricted Stock is awarded (the “Award
Date”) and ending on the earliest of the first to occur of the following:

 

    	15

    	 

    

 

a.            the
retirement of the Non-Employee Director from the Board in compliance with the Board’s retirement policy as then in effect;

 

b.            the
termination of the Non-Employee Director’s service on the Board as a result of the Non-Employee Director’s not being
nominated for reelection by the Board;

 

c.            the
termination of the Non-Employee Director’s service on the Board because of the Non-Employee Director’s resignation
or failure to stand for reelection with the consent of the Company’s Board (which means approval by at least 80% of the Directors
voting, with the affected Non-Employee Director abstaining);

 

d.            the
termination of the Non-Employee Director’s service on the Board because the Non-Employee Director, although nominated for
reelection by the Board, is not reelected by the stockholders;

 

e.            the
termination of the Non-Employee Director’s service on the Board because of (i) the Non-Employee’s Director’s
resignation at the request of the Nominating and Governance Committee of the Board (or successor committee), (ii) the Non-Employee
Director’s removal by action of the stockholders or by the Board, or (iii) a Change in Control of the Company;

 

f.            the
termination of the Non-Employee Director’s service on the Board because of Disability or death; or

 

g.           the
vesting of the Restricted Stock.

 

Section VIII.I.3.a.
through g. above are subject to the further restrictions that a removal or resignation for “Cause” will be deemed to
not constitute completion of the Period of Restriction and will result in a forfeiture of Restricted Stock not previously vested
under Section VIII.I.4. For purposes of this Plan, “Cause” will be a good faith determination by the Board that the
Non-Employee Director (i) failed to substantially perform his or her duties (other than a failure resulting from his or her incapacity
due to physical or mental illness) after a written demand for substantial performance has been delivered to him or her by the Board,
which demand specifically identifies the manner in which the Board believes such Non-Employee Director has not substantially performed
his or her duties; (ii) has engaged in conduct the consequences of which are materially adverse to the Company, monetarily or otherwise;
or (iii) has pleaded guilty or nolo contendere to or been convicted of a felony. The Non-Employee Director will not be deemed
to have been terminated for Cause unless there will have been delivered to the Non-Employee Director a letter from the Board setting
forth the reasons for the Company’s termination of the Non-Employee Director for Cause and, with respect to (i) or (ii),
stating that the Non-Employee Director has failed to cure such reason for termination within thirty (30) days after the Non-Employee
Director’s receipt of such notice.

 

    	16

    	 

    

 

4.           FORFEITURE
OF RESTRICTED STOCK. As of the date (“Termination Date”) a Non-Employee Director ceases to be a member of the Board
for any reason, including but not limited to removal or resignation for Cause, the Non-Employee Director shall forfeit to the Company
all Restricted Stock awarded to the Non-Employee Director for which the Period of Restriction has not ended pursuant to Section
VIII.I.3. as of or prior to the Termination Date.

 

IX.         RESTRICTED
STOCK UNITS

 

A.          GRANT
OF RESTRICTED STOCK UNITS. Subject to the terms of the Plan, RSUs may be granted to Participants in such amounts and upon such
terms, and at any time and from time to time, as shall be determined by the Committee. For purposes of this Article IX, the term
“Participant” shall include Non-Employee Directors of the Company and consultants.

 

B.           RESTRICTED
STOCK UNIT AGREEMENT. Each RSU grant shall be evidenced by a Restricted Stock Unit Award Agreement that shall specify the Period(s)
of Restriction, the number of RSUs granted, and such other provisions as the Committee may determine.

 

C.           VALUE
OF RESTRICTED STOCK UNIT. Each RSU shall have a value that is equal to the Fair Market Value of a Share on the date of grant.

 

D.           FORM
AND TIMING OF PAYMENT OF RESTRICTED STOCK UNITS. Settlement of vested RSUs may be made in the form of (i) cash, (ii) Shares or
(iii) any combination of both, as determined by the Committee at the time of the grant of the RSUs, in its sole discretion. Vested
RSUs shall be settled in a lump sum as soon as administratively practicable after the vesting date, but in no event later than
two and one-half (2 1⁄2) months following the vesting date. The amount of such settlement shall be equal to the Fair Market
Value of the RSUs on the vesting date.

 

E.           DIVIDEND
EQUIVALENTS. Each RSU shall be credited with an amount equal to the dividends paid on a Share between the date of grant and the
date such RSU is paid to the Participant (if at all). Dividend equivalents shall vest, if at all, upon the same terms and conditions
governing the vesting of RSUs under the Plan. Payment of the dividend equivalent shall be made at the same time as payment of the
RSU and shall be made without interest or other adjustment. If the RSU is forfeited, the Participant shall have no right to dividend
equivalents.

 

F.           VOTING
RIGHTS. The holders of RSUs shall have no voting rights.

 

    	17

    	 

    

 

G.           NONTRANSFERABILITY.
RSUs may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by laws of
descent and distribution.

 

X.          PERFORMANCE
UNITS AND PERFORMANCE SHARES

 

A.           GRANT
OF PERFORMANCE UNITS/SHARES. Subject to the terms of the Plan, Performance Units and/or Performance Shares may be granted to Participants
in such amounts and upon such terms, and at any time and from time to time, as shall be determined by the Committee.

 

B.           PERFORMANCE
UNIT/SHARE AGREEMENT. Each Performance Unit or Performance Share grant shall be evidenced by a Performance Unit or Performance
Share Award Agreement, as the case may be, that shall specify the number of Performance Units or Performance Shares granted and
such other provisions as the Committee may determine.

 

C.           VALUE
OF PERFORMANCE UNITS/SHARES. Each Performance Unit shall have an initial value that is established by the Committee at the time
of grant. Each Performance Share shall have an initial value equal to the Fair Market Value of a Share on the date of grant. The
Committee shall set performance goals in its discretion which, depending on the extent to which they are met, will determine the
number and/or value of Performance Units/Shares that will be paid out to the Participant. For purposes of this Article X, the time
period during which the performance goals must be met shall be called a “Performance Period.”

 

D.           EARNING
OF PERFORMANCE UNITS/SHARES. Subject to the terms of this Plan, after the applicable Performance Period has ended, the holder of
Performance Units/Shares shall be entitled to receive payout on the number and value of Performance Units/Shares earned by the
Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance goals
have been achieved.

 

E.           FORM
AND TIMING OF PAYMENT OF PERFORMANCE UNITS/SHARES. Payment of earned Performance Units/Shares shall be made in a single lump sum
following the close of the applicable Performance Period. Subject to the terms of this Plan, the Committee, in its sole discretion,
may pay earned Performance Units/Shares in the form of cash or in Shares (or in a combination thereof) which have an aggregate
Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period.
Such Shares may be granted subject to any restrictions deemed appropriate by the Committee. The determination of the Committee
with respect to the form of payout of such Awards shall be set forth in the Award Agreement pertaining to the grant of the Award.
Payment shall be made no later than two and one-half (2 1⁄2) months following the close of the Performance Period.

 

F.           SEPARATION
FROM SERVICE DUE TO DEATH OR DISABILITY. In the event the Participant incurs a Separation From Service by reason of death or Disability
during a Performance Period, the Participant shall not receive a payout of the Performance Units/Shares, unless determined otherwise
by the Committee or set forth in the Participant’s Award Agreement.

 

    	18

    	 

    

 

Payment of earned Performance
Units/Shares shall be made at a time specified by the Committee in its sole discretion and set forth in the Participant’s
Award Agreement.

 

G.           TERMINATION
OF EMPLOYMENT FOR OTHER REASONS. In the event that a Participant’s employment terminates for any reason other than those
reasons set forth in Section X.F. herein, all Performance Units/Shares intended to qualify for the Performance-Based Exception
shall be forfeited by the Participant to the Company.

 

H.           NONTRANSFERABILITY.
Except as otherwise provided in a Participant’s Award Agreement, Performance Units/Shares may not be sold, transferred, pledged,
assigned or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution. Further, except
as otherwise provided in a Participant’s Award Agreement, a Participant’s rights under the Plan shall be exercisable
during the Participant’s lifetime only by the Participant or the Participant’s legal representative.

 

I.           NO
DIVIDEND AND VOTING RIGHTS. Participants will not be entitled to receive any dividends declared with respect to Shares which have
been earned in connection with grants of Performance Units and/or Performance Shares, but not yet distributed to Participants nor
shall Participants have voting rights with respect to such Shares.

 

XI.         PERFORMANCE
MEASURES

 

Unless and until the Committee
proposes for stockholder vote and the Company’s stockholders approve a change in the general performance measures set forth
in this Article XI, the attainment of which may determine the degree of payout and/or vesting with respect to Awards to Covered
Employees which measures are designed to qualify for the Performance-Based Exception, the performance measure(s) to be used for
purposes of such grants may be measured at the Company level, at a Subsidiary or Affiliate level, or at an operating unit level
and shall be chosen from among the following: net income either before or after taxes (including adjusted net income), share price,
earnings per share (basic or diluted), total stockholder return, return on assets, return on equity, operating income, return on
capital or investment, cash flow or adjusted cash flow from operations, economic value added or adjusted cash flow per Share (net
income plus or minus change in operating assets and liabilities), debt level, cost reduction targets, and equity ratios.

 

The Committee shall have
the discretion to adjust the determinations of the degree of attainment of the preestablished performance goals; provided, however,
that Awards which are designed to qualify for the Performance-Based Exception, and which are held by Covered Employees, may not
be adjusted upward (the Committee shall retain the discretion to adjust such Awards downward).

 

In the event that applicable
tax and/or securities laws or exchange listing standards change to permit Committee discretion to alter the governing performance
measures without obtaining stockholder approval of such changes, the Committee shall have sole discretion to make such changes
without obtaining stockholder approval. In addition, in the event that the Committee determines that it is advisable to grant Awards
which shall not qualify for the Performance-Based Exception, the Committee may make such grants without satisfying the requirements
of Code Section 162(m).

 

    	19

    	 

    

 

In the case of any Award
which is granted subject to the condition that a specified performance measure be achieved, no payment under such Award shall be
made prior to the time that the Committee certifies in writing that the performance measure has been satisfied, in accordance with
Internal Revenue Service requirements. No such certification is required, however, in the case of an Award that is based solely
on an increase in the value of a Share from the date such Award was made.

 

XII.        BENEFICIARY
DESIGNATION

 

Each Participant under
the Plan may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom
any benefit under the Plan is to be paid in case of his or her death before he or she receives any or all of such benefit. Each
such designation shall revoke all prior designations by the same Participant, shall be in a form prescribed by the Company, and
will be effective only when filed by the Participant in writing with the Company during the Participant’s lifetime. In the
absence of any such designated beneficiary, benefits remaining unpaid at the Participant’s death shall be paid to the Participant’s
estate.

 

XIII.       DEFERRALS

 

The Committee may permit
or require a Participant to defer such Participant’s receipt of the payment of cash or the delivery of Shares that would
otherwise be due to such Participant by virtue of the exercise of an Option or SAR, the lapse or waiver of restrictions with respect
to Restricted Stock or Restricted Stock Units, or the satisfaction of any requirements or goals with respect to Performance Units/Shares.
If any such deferral election is required or permitted, the Committee shall, in its sole discretion, establish rules and procedures
for such payment deferrals, provided, however, all deferrals shall be made in accordance with all applicable requirements of Code
Section 409A or any guidance promulgated thereunder.

 

XIV.       RIGHTS
OF EMPLOYEES

 

A.           EMPLOYMENT.
Nothing in the Plan shall interfere with or limit in any way the right of the Company to terminate any Participant’s employment
at any time, nor confer upon any Participant any right to continue in the employ of the Company.

 

B.           PARTICIPATION.
No Employee shall have the right to be selected to receive an Award under this Plan or, having been so selected, to be selected
to receive a future Award.

 

XV.        AMENDMENT,
MODIFICATION, TERMINATION AND ADJUSTMENTS

 

A.           AMENDMENT,
MODIFICATION, AND TERMINATION. Subject to the terms of the Plan, the Board, upon recommendation of the Committee, may at any time
and from time to time, alter, amend, suspend or terminate the Plan in whole or in part for any purpose which the Committee deems
appropriate and that is otherwise consistent with Code Section 409A; provided, however, no amendment shall, without shareholder
approval, (i) materially increase the benefits accruing to Participants under the Plan; (ii) materially increase the number of
securities which may be issued under the Plan; or (iii) materially modify the requirements for participation in the Plan.

 

    	20

    	 

    

 

Except in connection with
a corporate transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash
dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, or exchange of shares), the
terms of outstanding Awards may not be amended to reduce the exercise price of outstanding Options or SARs or cancel outstanding
Options or SARs in exchange for cash, other awards or Options or SARs with an exercise price that is less than the exercise price
of the original Options or SARs without shareholder approval.

 

B.           ADJUSTMENT
OF AWARDS UPON THE OCCURRENCE OF CERTAIN UNUSUAL OR NONRECURRING EVENTS. The Committee may make adjustments in the terms and conditions
of, and the criteria included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the events
described in Section IV.C. hereof) affecting the Company or the financial statements of the Company or of changes in applicable
laws, regulations or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to
prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan; provided that
unless the Committee determines otherwise, no such adjustment shall be authorized to the extent that such authority would be inconsistent
with the Plan or Awards meeting the requirements of Code Sections 162(m) and 409A, as from time to time amended.

 

C.           AWARDS
PREVIOUSLY GRANTED. Notwithstanding any other provision of the Plan to the contrary (but subject to Section XV.B. hereof), no termination,
amendment or modification of the Plan shall adversely affect in any material way any Award previously granted under the Plan without
the written consent of the Participant holding such Award.

 

D.           COMPLIANCE
WITH CODE SECTION 162(m). At all times when Code Section 162(m) is applicable, all Awards granted under this Plan shall comply
with the requirements of Code Section 162(m); provided, however, that in the event the Committee determines that such compliance
is not desired with respect to any Award or Awards available for grant under the Plan, then compliance with Code Section 162(m)
will not be required. In addition, in the event that changes are made to Code Section 162(m) to permit greater flexibility with
respect to any Award or Awards available under the Plan, the Committee may, subject to this Article XV, make any adjustments it
deems appropriate consistent with the changes made to Code Section 162(m).

 

    	21

    	 

    

 

XVI.       PAYMENT
OF PLAN AWARDS AND CONDITIONS THEREON

 

A.           EFFECT
OF COMPETITIVE ACTIVITY. Anything contained in the Plan to the contrary notwithstanding, unless otherwise covered in an employment
agreement by and between the Company and the Participant, with respect to any Participant who is an Employee, if the employment
of any Participant shall terminate, for any reason other than death, while any Award to such Participant is outstanding hereunder,
and such Participant has not yet received the Shares covered by such Award or otherwise received the full benefit of such Award,
such Participant, if otherwise entitled thereto, shall receive such Shares or benefit only if, during the entire period from the
date of such Participant’s termination to the date of such receipt, such Participant shall have earned such Award by making
himself or herself available, upon request, at reasonable times and upon a reasonable basis, to consult with, supply information
to, and otherwise cooperate with the Company or any Subsidiary or Affiliate thereof with respect to any matter that shall have
been handled by him or her or under his or her supervision while he or she was in the employ of the Company or of any Subsidiary
or Affiliate thereof.

 

B.           NONFULFILLMENT
OF COMPETITIVE ACTIVITY CONDITIONS; WAIVERS UNDER THE PLAN. In the event of a Participant’s nonfulfillment of any condition
set forth in Section XVI.A. hereof, such Participant’s rights under any Award shall be forfeited and canceled forthwith;
provided, however, that the nonfulfillment of such condition may at any time (whether before, at the time of, or subsequent to
termination of employment) be waived by the Committee upon its determination that in its sole judgment there shall not have been
and will not be any substantial adverse effect upon the Company or any Subsidiary or Affiliate thereof by reason of the nonfulfillment
of such condition.

 

XVII.     CHANGE
IN CONTROL

 

A.           TREATMENT
OF OUTSTANDING AWARDS. Notwithstanding any provisions in the Participant’s Employment Agreement to the contrary, but subject
to Section XVII.B. herein or the Plan governing the particular Award, upon the occurrence of a Change in Control:

 

1.           any
and all Options and SARs granted hereunder shall become fully-vested and immediately exercisable;

 

2.           any
Periods of Restriction and restrictions imposed on Restricted Stock or RSUs which are not intended to qualify for the Performance-Based
Exception shall lapse; and

 

3.           any
Award intended to qualify for the Performance-Based Exception shall be earned in accordance with the applicable Award Agreement.

 

B.           TERMINATION,
AMENDMENT AND MODIFICATIONS OF CHANGE-IN-CONTROL PROVISIONS. Notwithstanding any other provision of the Plan or any Award Agreement
provision, the provisions of this Article XVII may not be terminated, amended or modified on or after the date of an event, commencing
upon material discussions by the Board respecting a possible transaction that would result in a Change in Control, which is likely
to give rise to a Change in Control to affect adversely any Award theretofore granted under the Plan without the prior written
consent of the Participant with respect to said Participant’s outstanding Awards.

 

XVIII.    TAX
PROVISIONS

 

A.           TAX
WITHHOLDING. The Company shall have the power and the right to deduct or withhold, or require a Participant who is an Employee
to remit to the Company, an amount sufficient to satisfy federal, state and local taxes, domestic or foreign, required by law or
regulation to be withheld with respect to any taxable event arising as a result of this Plan.

 

    	22

    	 

    

 

B.           SHARE
WITHHOLDING. With respect to withholding required upon the exercise of Options or SARs, upon the lapse of restrictions on Restricted
Stock or Restricted RSUs, upon achievement of the performance goals on Performance Shares or Performance Units or upon any other
taxable event arising as a result of Awards granted hereunder, Participants who are Employees may elect, subject to the approval
of the Committee, to satisfy the withholding requirement, in whole or in part, by having the Company withhold Shares having a Fair
Market Value on the date the tax is to be determined at least equal to the minimum, but not more than the maximum, statutory tax
which could be imposed on the transaction. All such elections shall be irrevocable, made in writing, and signed by the Participant,
and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

 

C.           REQUIREMENT
OF NOTIFICATION OF CODE SECTION 83(b) ELECTION. If any Participants shall make an election under Code Section 83(b) (to include
in gross income in the year of transfer the amounts specified in Code Section 83(b)) or under a similar provisions of the laws
of a jurisdiction outside the United States, such Participant shall notify the Company of such election within ten (10) days after
filing notice of the election with the Internal Revenue Service or other government authority, in addition to any filing and notification
required pursuant to regulations issued under Code Section 83(b) or other applicable provision.

 

D.           REQUIREMENT
OF NOTIFICATION UPON DISQUALIFYING DISPOSITION UNDER CODE SECTION 421(b). If any Participant shall make any disposition of shares
of stock delivered pursuant to the exercise of an Incentive Stock Option under the circumstances described in Code Section 421(b)
(relating to certain disqualifying dispositions), such Participant shall notify the Company of such disposition within ten (10)
days thereof.

 

XIX.      INDEMNIFICATION

 

Each person who is or shall
have been a member of the Committee, or of the Board, shall be indemnified and held harmless by the Company against and from any
loss, cost, liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting
from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of
any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof,
with the Company’s approval, or paid by him or her in satisfaction of any judgment in any such action, suit or proceeding
against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same
before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not
be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Articles of
Incorporation or Bylaws, as a matter of law or otherwise, or any power that the Company may have to indemnify them or hold them
harmless.

 

    	23

    	 

    

 

XX.        SUCCESSORS

 

All obligations of the
Company under the Plan with respect to Awards granted hereunder shall be binding on any successor to the Company, whether the existence
of such successor is the result of a direct or indirect purchase, merger, consolidation or otherwise, of all or substantially all
of the business or assets of the Company.

 

XXI.       LEGAL
CONSTRUCTION

 

A.           GENDER
AND NUMBER. Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine, the
plural shall include the singular, and the singular shall include the plural.

 

B.           SEVERABILITY.
In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not
affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provision had
not been included.

 

C.           REQUIREMENTS
OF LAW. The granting of Awards and the issuance of Shares under the Plan shall be subject to all applicable laws, rules and regulations,
and to such approvals by any governmental agencies or national securities exchanges as may be required.

 

D.           SECURITIES
LAW COMPLIANCE. With respect to Insiders, transactions under this Plan are intended to comply with all applicable conditions of
Rule 16b-3 or its successors under the Exchange Act. To the extent any provision of the Plan or action by the Committee fails to
so comply, it shall be deemed null and void, to the extent permitted by law and deemed advisable by the Committee.

 

E.           CODE
SECTION 409A COMPLIANCE. Notwithstanding any other provision of this Plan to the contrary, all Awards under this Plan that are
subject to Code Section 409A shall be designed and administered in a manner that does not result in the imposition of tax or penalties
under Code Section 409A. Accordingly, Awards under this Plan that are subject to Code Section 409A shall comply with the following
requirements, as applicable.

 

1.           Distribution
to Specified Employees Upon Separation from Service. To the extent that payment under an Award which is subject to Code Section
409A is due to a Specified Employee on account of the Specified Employee’s Separation from Service from the Company or its
Affiliate or Subsidiary, such payment shall be delayed until the first day of the seventh (7th) month following such
Separation from Service (or as soon as practicable thereafter). The Committee, in its discretion, may provide in the Award document
for the payment of interest at a rate set by the Committee for such six-month period. In the event that a payment under an Award
is exempt from Code Section 409A, payment shall be made to a Specified Employee without any such six-month delay.

 

    	24

    	 

    

 

2.           No
Acceleration of Payment. To the extent that an Award is subject to Code Section 409A, payment under such Award shall not be
accelerated from the date(s) specified in the Award documents as of the date of grant.

 

3.           Subsequent
Delay in Payment. To the extent that an Award is subject to Code Section 409A, payment under such Award shall not be deferred
beyond the dates specified in the Award document as of the date of grant, unless the Committee or Participant, as the case may
be, makes the decision to delay payment at least one year prior to the scheduled payment date, and payment is delayed at least
five (5) years.

 

F.           GOVERNING
LAW. To the extent not preempted by federal law, the Plan, and all agreements hereunder, shall be construed in accordance with
and governed by the laws of the State of Delaware.

 

    	25This LOAN AND SECURITY AGREEMENT (the
“Agreement”) is entered into as of December 1, 2011, by and between Square 1 Bank (“Bank”) and Enumeral
Biomedical Corp. (“Borrower”).

 

RECITALS

 

Borrower wishes to obtain credit from
time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which Bank will advance
credit to Borrower, and Borrower will repay the amounts owing to Bank.

 

AGREEMENT

 

The parties agree as follows:

 

1.           DEFINITIONS
AND CONSTRUCTION.

 

1.1         Definitions.
As used in this Agreement, all capitalized terms shall have the definitions set forth on Exhibit A. Any term used in the Code
and not defined herein shall have the meaning given to the term in the Code.

 

1.2         Accounting
Terms. Any accounting term not specifically defined on Exhibit A shall be construed in accordance with GAAP and all calculations
shall be made in accordance with GAAP (except for non-compliance with FAS 123R in monthly reporting). The term “financial
statements” shall include the accompanying notes and schedules.

 

2.           LOAN
AND TERMS OF PAYMENT.

 

2.1         Credit
Extensions.

 

(a)          Promise
to Pay. Borrower promises to pay to Bank, in lawful money of the United States of America, the aggregate unpaid principal amount
of all Credit Extensions made by Bank to Borrower, together with interest on the unpaid principal amount of such Credit Extensions
at rates in accordance with the terms hereof.

 

(b)          Term
Loan A.

 

(i)          Subject
to and upon the terms and conditions of this Agreement, Bank agrees to make one (1) term loan to Borrower in an aggregate principal
amount of the Term Loan A Amount (“Term Loan A”). Borrower agrees to request Term Loan A on the Term Loan A Availability
End Date. The proceeds of the Term Loan A shall be used for general working capital purposes and for capital expenditures.

 

(ii)         Interest
shall accrue from the date of Term Loan A at the rate specified in Section 2.3(a), and prior to the Term Loan A Interest-Only End
Date interest only shall be payable monthly beginning on January 1, 2011, and continuing on the same day of each month thereafter.
If Term Loan A remains outstanding on the Term Loan A Interest-Only End Date, it shall be payable in 30 equal monthly installments
of principal, plus all accrued interest, beginning on one month immediately following the Term Loan A Interest-Only End Date,
and continuing on the same day of each month thereafter through the Term Loan A Maturity Date,
at which time all amounts due in connection with the Term Loan A shall be immediately due and payable. Term Loan A, once repaid,
may not be re-borrowed.

 

    	1.

    	 

    

(iii)        On
the Term Loan A Availability End Date, Borrower shall confirm to
Bank (which notice shall be irrevocable) by facsimile transmission to be received no later than 3:30 p.m. Eastern time that Borrower
desires to obtain Term Loan A. Such confirmation shall be substantially in the form of Exhibit C. The confirmation shall be signed
by an Authorized Officer.

 

(c)          Term
Loan B.

 

(i)          Subject
to and upon the terms and conditions of this Agreement, Bank agrees to make one (1) term loan to Borrower
in an aggregate principal amount of the Term Loan B Amount (“Term Loan B”). Borrower may request Term Loan
B at any time from the date hereof through the Term Loan B Availability End Date. The proceeds of Term Loan B shall be used for
general working capital purposes and for capital expenditures.

 

(ii)         Interest
shall accrue from the date of Term Loan B at the rate specified in Section 2.3(a), and prior to the Term Loan B Interest-Only
End Date for the applicable Term Loan B interest only shall be payable monthly beginning on the first day of the month next following
such Term Loan B, and continuing on the same day of each month thereafter. If Term Loan B remains outstanding on the Term Loan
B Interest-Only End Date, it shall be payable in 30 equal monthly installments of principal, plus all accrued interest, beginning
on one month immediately following the Term Loan B Interest-Only End Date, and continuing on the same day of each month thereafter
through the Term Loan B Maturity Date, at which time all amounts due in connection with the Term Loan B and any other amounts
due under this Agreement shall be immediately due and payable. Term Loan B, once repaid, may not be re-borrowed.

 

(iii)        When
Borrower desires to obtain Term Loan B, Borrower shall notify Bank (which notice shall be irrevocable) by facsimile transmission
to be received no later than 3:30 p.m. Eastern time on the day on which the Term Loan B is to be made. Such notice shall be substantially
in the form of Exhibit C. The notice shall be signed by an Authorized Officer and include evidence to Bank that Borrower has received
the New Equity in its entirety.

 

(d)          Equipment
Advances.

 

(i)          Subject
to and upon the terms and conditions of this Agreement, Bank agrees
to make Equipment Advances to Borrower. Borrower may request, and, subject to terms and conditions hereof, the satisfaction of
which shall be determined in good faith by Bank in its sole discretion, Bank will fund Equipment Advances at any time from the
date hereof through the Equipment Availability End Date. The aggregate outstanding amount of Equipment Advances shall not exceed
the Equipment Loan.

 

    	2.

    	 

    

 

(ii)         For
Equipment purchased by Borrower within 90 days of the date of the corresponding Equipment Advance, each Equipment Advance shall
not exceed 100.0% (the “Equipment Advance Rate”) of the invoice amount of equipment and software approved by Bank from
time to time, excluding any portion of Soft Costs that exceed of 10.0% of the Equipment Advance; provided however, that the Equipment
Advance Rate shall be decreased by 25.0% for Equipment aged 91-120 days from the invoice date and such Equipment Advance Rate shall
be further decreased by an additional 5.0% for each additional 30 days (or any part thereof) beyond 120 days from the invoice date;
and provided further however, that the Equipment Advance Rate applicable to the initial Equipment Advance shall not be subject
to the aforementioned discounting process if such Equipment Advance: (i) pertains to the approximately $590,000 of Equipment acquired
by the Borrower between May 1, 2011 and the Closing Date, (ii) occurs on or about the Closing Date, and (iii) the Closing Date
is on or before October 31, 2011. The Equipment Advance Rate and the eligibility of all Equipment as the basis for future Equipment
Advances are subject to modification in the Bank’s sole discretion based on Bank’s review of the Collateral.

 

(iii)        Interest
shall accrue from the date of each Equipment Advance at the rate specified in Section 2.3(a), and prior to the Equipment Interest-Only
End Date interest only shall be payable monthly beginning on the first day of the month next following the Equipment Advance, and
continuing on the first day of each month thereafter. Any Equipment Advances that are outstanding on the Equipment Interest-Only
End Date shall be payable in 30 equal monthly installments of principal, plus all accrued interest, beginning on the date one (1)
month immediately following the Equipment Interest-Only End Date, and continuing on the same day of each month thereafter through
the Equipment Maturity Date, at which time all amounts due in connection with the Equipment Advance shall be immediately due and
payable. Equipment Advances, once repaid, may not be reborrowed. Borrower may prepay any Equipment Advances without penalty or
premium.

 

(iv)        When
Borrower desires to obtain an Equipment Advance, Borrower shall notify Bank (which notice shall be irrevocable) by facsimile transmission
to be received no later than 3:00 p.m. Eastern time three Business Days before the day on which the Equipment Advance is
to be made. Such notice shall be substantially in the form of Exhibit C. The notice shall be signed by a Responsible Officer or
its designee and include a copy of the invoice for any Equipment to be financed.

 

2.2         Intentionally
Left Blank.

 

2.3         Interest
Rates, Payments, and Calculations.

 

(a)          Interest
Rates.

 

(i)          Equipment
Advances. Except as set forth in Section 2.3(b), the Equipment Advances shall bear interest, on the outstanding daily balance
thereof, at a variable annual rate equal to the greater of: (A) 3.75% above the Prime Rate then in effect; or (B) 7.00%; provided
however, subject to the condition that no Event of Default has occurred hereunder, that the annual rate shall not exceed 8.50%
during the first 18 months after the Closing Date and shall not exceed 9.50% thereafter.

 

    	3.

    	 

    

 

(ii)          Term
Loans. Except as set forth in Section 2.3(b), the Term Loans shall bear interest, on the outstanding daily balance thereof,
at a variable annual rate equal to the greater of: (A) 3.75% above the Prime Rate then in effect; or (B) 7.00%; provided however,
subject to the condition that no Event of Default has occurred hereunder, that the annual rate shall not exceed 8.50% during the
first 18 months after the Closing Date and shall not exceed 9.50% thereafter.

 

(a)          Late
Fee; Default Rate. If any payment is not made within 15 days after the date such payment is due, Borrower shall pay Bank a
late fee equal to the lesser of (i) 5% of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under
applicable law. All Obligations shall bear interest, from and after the occurrence and during the continuance of an Event of Default,
at a rate equal to 5 percentage points above the interest rate applicable immediately prior to the occurrence of the Event of Default.

 

(b)          Payments.
Bank shall, at its option, charge such interest, all Bank Expenses, and all Periodic Payments against any of Borrower’s
deposit accounts. Any interest not paid when due shall be compounded by becoming a part of the Obligations, and such interest shall
thereafter accrue interest at the rate then applicable hereunder.

 

(c)          Computation.
In the event the Prime Rate is changed from time to time hereafter, the applicable rate of interest hereunder shall be increased
or decreased, effective as of the day the Prime Rate is changed, by an amount equal to such change in the Prime Rate. All interest
chargeable under the Loan Documents shall be computed on the basis of a 360 day year for the actual number of days elapsed.

 

2.4         Crediting
Payments. Prior to the occurrence of an Event of Default, Bank shall credit a wire transfer of funds, check or other item of
payment to such deposit account or Obligation as Borrower specifies, except that to the extent Borrower uses the Equipment Advances/Term
Loans to purchase Collateral, Borrower’s repayment of the Equipment Advances/Term Loans shall apply on a “first-in-first-out”
basis so that the portion of the Equipment Advances/Term Loans used to purchase a particular item of Collateral shall be paid in
the chronological order the Borrower purchased the Collateral. After the occurrence and during the continuance of an Event of Default,
Bank shall have the right, in its sole discretion, to immediately apply any wire transfer of funds, check, or other item of payment
Bank may receive to conditionally reduce Obligations, but such applications of funds shall not be considered a payment on account
unless such payment is of immediately available federal funds or unless and until such check or other item of payment is honored
when presented for payment. Notwithstanding anything to the contrary contained herein, any wire transfer or payment received by
Bank after 5:30 p.m. Eastern time shall be deemed to have been received by Bank as of the opening of business on the immediately
following Business Day. Whenever any payment to Bank under the Loan Documents would otherwise be due (except by reason of acceleration)
on a date that is not a Business Day, such payment shall instead be due on the next Business Day, and additional fees or interest,
as the case may be, shall accrue and be payable for the period of such extension.

 

    	4.

    	 

    

 

2.5           Fees.
Borrower shall pay to Bank the following:

 

(a)          Facility
Fee. On or before the Closing Date, a fee equal to $10,000, which shall be nonrefundable;

 

(b)          Bank
Expenses. On the Closing Date, all Bank Expenses incurred through the Closing Date, and, after the Closing Date, all Bank
Expenses, as and when they become due.

 

(c)          Prepayment
Fee. In the event Borrower prepays all or a portion of any Term Loans prior to the Term Loan Maturity Date, Borrower shall,
simultaneous with any such prepayment, pay Bank a fee of: (i) 3.0% of the aggregate principal amount so prepaid if such prepayment
occurs during the first year after the Closing Date; (ii) 2.0% of the aggregate principal amount so prepaid if such prepayment
occurs during the second year after the Closing Date; or (iii) 1.0% of the aggregate principal amount so prepaid if such prepayment
occurs during the third year after the Closing Date.

 

2.6           Term.
This Agreement shall become effective on the Closing Date and, subject to Section 12.7, shall continue in full force and effect
for so long as any Obligations remain outstanding or Bank has any obligation to make Credit Extensions under this Agreement. Notwithstanding
the foregoing, Bank shall have the right to terminate its obligation to make further Credit Extensions under this Agreement immediately
and without notice upon the occurrence and during the continuance of an Event of Default.

 

3.           CONDITIONS
OF LOANS.

 

3.1         Conditions
Precedent to Closing. The agreement of Bank to enter into this Agreement on the Closing Date is subject to the condition precedent
that Bank shall have received, in form and substance satisfactory to Bank, each the following items and completed each of the following
requirements:

 

(a)          this
Agreement;

 

(b)         an
officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution and delivery of this
Agreement;

 

(c)        
a financing statement (Form UCC-1);

 

(d)        
payment of the fees and Bank Expenses then due specified in Section 2.5, which may be debited from any of Borrower’s accounts
with Bank;

 

(e)         current
SOS Reports indicating that except for Permitted Liens, there are no other security interests or Liens of record in the Collateral;

 

(f)          current
financial statements, including statements (or such other level required by the Investment Agreement) for Borrower’s most
recently ended fiscal year, together with an unqualified opinion (or an opinion qualified only for going concern), company prepared
consolidated and consolidating balance sheets and income statements for the most recently ended month in accordance with Section
6.2, and such other updated financial information as Bank may reasonably request;

 

    	5.

    	 

    

 

(g)         current
Compliance Certificate in accordance with Section 6.2;

 

(h)         a
Warrant in form and substance satisfactory to Bank;

 

(i)          a
Borrower Information Certificate;

 

(j)          Borrower
shall have opened and funded not less than $50,000 in deposit accounts held with Bank; and

 

(k)         such
other documents or certificates, and completion of such other matters, as Bank may reasonably request.

 

3.2         Conditions
Precedent to all Credit Extensions. The obligation of Bank to make each Credit Extension, including the initial Credit Extension,
is contingent upon the Borrower’s compliance with Section 3.1 above, and is further subject to the following conditions:

 

(a)          timely
receipt by Bank of the Loan Advance/Paydown Request Form as provided in Section 2.1;

 

(b)          Borrower
shall have transferred substantially all of its Cash assets into operating accounts held with Bank and otherwise be in compliance
with Section 6.6 hereof;

 

(c)          prior
to the making of Term Loan B only, delivery of evidence to Bank that Borrower has received the New Equity in its entirety; and

 

(d)          the
representations and warranties contained in Section 5 shall be true and correct in all material respects on and as of the date
of such Loan Advance/Paydown Request Form and on the effective date of each Credit Extension as though made at and as of each
such date, and no Event of Default shall have occurred and be continuing, or would exist after giving effect to such Credit Extension
(provided, however, that those representations and warranties expressly referring to another date shall be true, correct and complete
in all material respects as of such date). The making of each Credit Extension shall be deemed to be a representation and warranty
by Borrower on the date of such Credit Extension as to the accuracy of the facts referred to in this Section 3.2.

 

4.           CREATION
OF SECURITY INTEREST.

 

4.1         Grant
of Security Interest. Borrower grants and pledges to Bank a continuing security interest in the Collateral to secure prompt
repayment of any and all Obligations and to secure prompt performance by Borrower of each of its covenants and duties under the
Loan Documents. Except for Permitted Liens or as disclosed in the Schedule, such security interest constitutes a valid, first priority
security interest in the presently existing Collateral, and will constitute a valid, first priority security interest in later-acquired
Collateral. Borrower also hereby agrees not to sell, transfer, assign, mortgage, pledge, lease, grant a security interest in, or
encumber any of its Intellectual Property. Notwithstanding any termination of this Agreement or of any filings undertaken related
to Bank’s rights under the Code, Bank’s Lien on the Collateral shall remain in effect for so long as any Obligations
are outstanding.

 

    	6.

    	 

    

4.2          Perfection
of Security Interest. Borrower authorizes Bank to file at any time financing statements, continuation statements, and amendments
thereto that (i) either specifically describe the Collateral or describe the Collateral as all assets of Borrower of the kind pledged
hereunder, and (ii) contain any other information required by the Code for the sufficiency of filing office acceptance of any financing
statement, continuation statement, or amendment, including whether Borrower is an organization, the type of organization and any
organizational identification number issued to Borrower, if applicable. Borrower shall have possession of the Collateral, except
where expressly otherwise provided in this Agreement or where Bank chooses to perfect its security interest by possession in addition
to the filing of a financing statement. Where Collateral is in possession of a third party bailee, Borrower shall take such steps
as Bank reasonably requests for Bank to (i) subject to Section 7.10 below, obtain an acknowledgment, in form and substance satisfactory
to Bank, of the bailee that the bailee holds such Collateral for the benefit of Bank, and (ii) obtain “control” of
any Collateral consisting of investment property, deposit accounts, letter-of-credit rights or electronic chattel paper (as such
items and the term “control” are defined in Revised Article 9 of the Code) by causing the securities intermediary or
depositary institution or issuing bank to execute a control agreement in form and substance satisfactory to Bank. Borrower will
not create any chattel paper without placing a legend on the chattel paper acceptable to Bank indicating that Bank has a security
interest in the chattel paper. Borrower from time to time may deposit with Bank specific cash collateral to secure specific Obligations;
Borrower authorizes Bank to hold such specific balances in pledge and to decline to honor any drafts thereon or any request by
Borrower or any other Person to pay or otherwise transfer any part of such balances for so long as the specific Obligations are
outstanding. Borrower shall take such other actions as Bank requests to perfect its security interests granted under this Agreement.

 

5.           REPRESENTATIONS
AND WARRANTIES.

 

Borrower represents and warrants
as follows:

 

5.1         Due
Organization and Qualification. Borrower and each Subsidiary is a corporation duly existing under the laws of the state in
which it is organized and qualified and licensed to do business in any state in which the conduct of its business or its ownership
of property requires that it be so qualified, except where the failure to do so would not reasonably be expected to cause a Material
Adverse Effect.

 

5.2         Due
Authorization; No Conflict. The execution, delivery, and performance of the Loan Documents are within Borrower’s powers,
have been duly authorized, and are not in conflict with nor constitute a breach of any provision contained in Borrower’s
Certificate of Incorporation or Bylaws, nor will they constitute an event of default under any material agreement by which Borrower
is bound. Borrower is not in default under any agreement by which it is bound, except to the extent such default would not reasonably
be expected to cause a Material Adverse Effect.

 

    	7.

    	 

    

5.3           Collateral.
Borrower has rights in or the power to transfer the Collateral, and its title to the Collateral is free and clear of Liens,
adverse claims, and restrictions on transfer or pledge except for Permitted Liens. Other than movable items of personal property,
for example such as laptop computers, all Collateral having an aggregate book value not in excess of $100,000, is located solely
in the Collateral States. All Inventory is in all material respects of good and merchantable quality, free from all material defects,
except for Inventory for which adequate reserves have been made. Except as set forth in the Schedule, none of the Borrower’s
Cash is maintained or invested with a Person other than Bank or Bank’s affiliates.

 

5.4           Intellectual
Property. Borrower is the sole owner of the intellectual property created or purchased by Borrower, except for licenses granted
by Borrower to its customers, strategic partners, contractors, and other third parties. To the best of Borrower’s knowledge,
each of the Copyrights, Trademarks and Patents created or purchased by Borrower is valid and enforceable, and no part of the intellectual
property created or purchased by Borrower has been judged invalid or unenforceable, in whole or in part, and, to the best of Borrower’s
knowledge, no claim has been made to Borrower that any part of the intellectual property created or purchased by Borrower violates
the rights of any third party except to the extent such claim would not reasonably be expected to cause a Material Adverse Effect.

 

5.5          Name;
Location of Chief Executive Office. Except as disclosed in the Schedule, Borrower has not done business under any name other
than that specified on the signature page hereof, and its exact legal name is as set forth in the first paragraph of this Agreement.
The chief executive office of Borrower is located at the address indicated in Section 10 hereof.

 

5.6          Litigation.
Except as set forth in the Schedule, there are no actions or proceedings pending by or against Borrower or any Subsidiary before
any court or administrative agency in which a likely adverse decision would reasonably be expected to have a Material Adverse Effect.

 

5.7          No
Material Adverse Change in Financial Statements. All consolidated and consolidating financial statements related to Borrower
and any Subsidiary that are delivered by Borrower to Bank fairly present in all material respects Borrower’s consolidated
and consolidating financial condition as of the date thereof and Borrower’s consolidated and consolidating results of operations
for the period then ended. There has not been a material adverse change in the consolidated or in the consolidating financial
condition of Borrower since the date of the most recent of such financial statements submitted to Bank.

 

5.8          Solvency,
Payment of Debts. Borrower is able to pay its debts (including trade debts) as they mature; the fair saleable value of Borrower’s
assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; and Borrower is not left with unreasonably
small capital after the transactions contemplated by this Agreement.

 

    	8.

    	 

    

5.9         Compliance
with Laws and Regulations. Borrower and each Subsidiary have met the minimum funding requirements of ERISA with respect
to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA
that is reasonably likely to result in Borrower’s incurring any liability that could have a Material Adverse Effect. Borrower
is not an “investment company” or a company “controlled” by an “investment company” within
the meaning of the Investment Company Act of 1940. Borrower is not engaged principally, or as one of its important activities,
in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations
T and U of the Board of Governors of the Federal Reserve System). Borrower has not violated any statutes, laws, ordinances or
rules applicable to it, the violation of which would reasonably be expected to have a Material Adverse Effect. Borrower and each
Subsidiary have filed or caused to be filed all tax returns required to be filed, and have paid, or have made adequate provision
for the payment of, all taxes reflected therein except those being contested in good faith with adequate reserves under GAAP or
where the failure to file such returns or pay such taxes would not reasonably be expected to have a Material Adverse Effect.

 

5.10       Subsidiaries.
Borrower does not own any stock, partnership interest or other equity securities of any Person, except for Permitted Investments.

 

5.11       Government
Consents. Borrower and each Subsidiary have obtained all consents, approvals and authorizations of, made all declarations or
filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s
business as currently conducted, except where the failure to do so would not reasonably be expected to cause a Material Adverse
Effect.

 

5.12       Inbound
Licenses. Except as disclosed on the Schedule, Borrower is not a party to, nor is bound by, any material license or other agreement
important for the conduct of Borrower’s business that prohibits or otherwise restricts Borrower from granting a security
interest in Borrower’s interest in such license or agreement or any other property important for the conduct of Borrower’s
business, other than this Agreement or the other Loan Documents.

 

5.13       Full
Disclosure. No representation, warranty or other statement made by Borrower in any certificate or written statement furnished
to Bank taken together with all such certificates and written statements furnished to Bank contains any untrue statement of a material
fact or omits to state a material fact necessary in order to make the statements contained in such certificates or statements not
misleading in light of the circumstances in which they were made, it being recognized by Bank that the projections and forecasts
provided by Borrower in good faith and based upon reasonable assumptions are not to be viewed as facts and that actual results
during the period or periods covered by any such projections and forecasts may differ from the projected or forecasted results.

 

6.           AFFIRMATIVE COVENANTS.

 

Borrower covenants that, until payment
in full of all outstanding Obligations, and for so long as Bank may have any commitment to make a Credit Extension hereunder, Borrower
shall do all of the following:

 

    	9.

    	 

    

6.1         Good
Standing and Government Compliance. Borrower shall maintain its and each of its Subsidiaries’ corporate existence
and good standing in the respective states of formation, shall maintain qualification and good standing in each other jurisdiction
in which the failure to so qualify would reasonably be expected to have a Material Adverse Effect, and shall furnish to Bank the
organizational identification number issued to Borrower by the authorities of the state in which Borrower is organized, if applicable.
Borrower shall meet, and shall cause each Subsidiary to meet, the minimum funding requirements of ERISA with respect to any employee
benefit plans subject to ERISA. Borrower shall comply, and shall cause each Subsidiary to comply, with all statutes, laws, ordinances
and government rules and regulations to which it is subject, and shall maintain, and shall cause each of its Subsidiaries to maintain,
in force all licenses, approvals and agreements, the loss of which or failure to comply with which would reasonably be expected
to have a Material Adverse Effect.

 

6.2         Financial
Statements, Reports, Certificates. Borrower shall deliver to Bank: (i) as soon as available, but in any event within
30 days after the end of each calendar month, a company prepared consolidated and consolidating balance sheet, cash flow statement
and income statement covering Borrower’s operations during such period, in a form reasonably acceptable to Bank and certified
by a Responsible Officer; (ii) as soon as available, but in any event within 180 days after the end of Borrower’s fiscal
year, audited (or such other level as is required by the Investment Agreement) consolidated and consolidating financial statements
of Borrower prepared in accordance with GAAP, consistently applied, together with an opinion on such financial statements of an
independent certified public accounting firm reasonably acceptable to Bank which is either unqualified or qualified only for going
concern, so long as in the case of the qualified opinion it is either consented to in writing by Bank or in the alternative if
following the delivery of such financial statements the Bank does not consent to such qualified Borrower’s investors will
provide additional equity as needed within 30 days after notice from the Bank of such non consent to the qualified financial statements
or otherwise; (iii) annual budget approved by Borrower’s Board of Directors as soon as available but not later than 30 days
before the beginning of the applicable calendar year, provided however, that for the 2012 annual budget only, Borrower shall provide
the 2012 annual budget approved by Borrower’s Board of Directors as soon as available but not later than March 1, 2012; (iv)
if applicable, copies of all statements, reports and notices sent or made available generally by Borrower to its security holders
or to any holders of Subordinated Debt and all reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission;
(v) promptly upon receipt of notice thereof, a report of any legal actions pending or threatened against Borrower or any Subsidiary
that could reasonably be expected to result in damages or costs to Borrower or any Subsidiary of $250,000 or more; (vi) promptly
upon receipt, each management letter prepared by Borrower’s independent certified public accounting firm regarding Borrower’s
management control systems, (vii) such budgets, sales projections, operating plans or other financial information generally prepared
by Borrower in the ordinary course of business as Bank may reasonably request from time to time.

 

(a)          Within
30 days after the last day of each month, Borrower shall deliver to Bank with the monthly financial statements a Compliance Certificate
certified as of the last day of the applicable month and signed by a Responsible Officer in substantially the form of Exhibit
D hereto.

 

(b)          As
soon as possible and in any event within three (3) Business days after becoming aware of the occurrence or existence of an Event
of Default hereunder, a written statement of a Responsible Officer setting forth details of the Event of Default, and the action
which Borrower has taken or proposes to take with respect thereto.

 

    	10.

    	 

    

 

(c)          If
an Event of Default has occurred and is continuing, Bank (through any of its officers, employees, or agents) shall have the right
to inspect Borrower’s Books and to make copies thereof and to check, test, inspect, audit and appraise the Collateral at
Borrower’s expense in order to verify Borrower’s financial condition or the amount, condition of, or any other matter
relating to, the Collateral.

 

Borrower may deliver to Bank on an electronic
basis any certificates, reports or information required pursuant to this Section 6.2, and Bank shall be entitled to rely on the
information contained in the electronic files, provided that Bank in good faith believes that the files were delivered by a Responsible
Officer. Borrower shall include a submission date on any certificates and reports to be delivered electronically.

 

6.3          Inventory
and Equipment; Returns. Borrower shall keep all Inventory and Equipment in good and merchantable condition, free from all material
defects except for Inventory and Equipment (i) sold in the ordinary course of business, and (ii) for which adequate reserves have
been made, in all cases in the United States and such other locations as to which Borrower gives prior written notice. Returns
and allowances, if any, as between Borrower and its account debtors shall be on the same basis and in accordance with the usual
customary practices of Borrower, as they exist on the Closing Date. Borrower shall promptly notify Bank of all returns and recoveries
and of all disputes and claims involving inventory having a book value of more than $100,000.

 

6.4          Taxes.
Borrower shall make, and cause each Subsidiary to make, due and timely payment or deposit of all material federal, state, and
local taxes, assessments, or contributions required of it by law, including, but not limited to, those laws concerning income taxes,
F.I.C.A., F.U.T.A. and state disability, and will execute and deliver to Bank, on demand, proof satisfactory to Bank indicating
that Borrower or a Subsidiary has made such payments or deposits and any appropriate certificates attesting to the payment or deposit
thereof; provided that Borrower or a Subsidiary need not make any payment if the amount or validity of such payment is contested
in good faith by appropriate proceedings and is reserved against (to the extent required by GAAP) by Borrower or such Subsidiary.

 

6.5         Insurance. Borrower, at its expense, shall (i) keep the Collateral insured against loss or
damage, and (ii) maintain liability and other insurance, in each case in as ordinarily insured against by other owners in
businesses similar to Borrower’s. All such policies of insurance shall be in such form, with such companies, and in
such amounts as reasonably satisfactory to Bank. All policies of property insurance shall contain a lender’s loss
payable endorsement, in a form satisfactory to Bank, showing Bank as an additional loss payee, and all liability insurance
policies shall show Bank as an additional insured and specify that the insurer must give at least 10 days notice to Bank
before canceling its policy for any reason. Within 30 days of the Closing Date, Borrower shall cause to be furnished to Bank
a copy of its policies or certificate of insurance including any endorsements covering Bank or showing Bank as an additional
insured. Upon Bank’s request, Borrower shall deliver to Bank certified copies of the policies of insurance and evidence
of all premium payments. Proceeds payable under any casualty policy covering the Collateral will, at Borrower’s option,
be payable to Borrower to replace the property subject to the claim, provided that any such replacement property shall be
deemed Collateral in which Bank has been granted a first priority security interest, provided that if an Event of Default has
occurred and is continuing, all proceeds payable under any such policy shall, at Bank’s option, be payable to Bank to
be applied on account of the Obligations.

 

    	11.

    	 

    

 

6.6          “Primary
Depository”. Subject to the provisions of Section 3.1(j) and 3.2(b), Borrower within 30 days of the Closing Date shall
maintain all its depository and operating accounts with Bank and its primary investment accounts with Bank or Bank’s affiliates.

 

6.7          Financial
Covenants. Borrower shall at all times maintain at least one of the following financial ratios and covenants:

 

(a)          Liquidity
Ratio. A Liquidity Ratio of at least 1.25 to 1.00; or

 

(b)          Cash
Burn. Tested monthly and calculated on a trailing six-months average, a Cash Burn of not more than the amounts shown in column
B below for the corresponding reporting period in column A.

 

	A	 	B	 
	Reporting Period Ending On	 	Maximum Cash Burn	 
	August 31, 2011	 	$	1,720,400	 
	September 30, 2011	 	$	1,897,700	 
	October 31, 2011	 	$	2,123,300	 
	November 30, 2011	 	$	2,457,900	 
	December 31, 2011	 	$	1,907,600	 
	January 31, 2012	 	$	1,935,400	 
	February 29, 2012	 	$	1,884,900	 
	March 31, 2012	 	$	1,651,000	 
	April 30, 2012	 	$	1,699,300	 
	May 31, 2012	 	$	1,658,900	 
	June 30, 2012	 	$	1,584,100	 
	July 31, 2012	 	$	1,288,200	 
	August 31, 2012	 	$	1,288,800	 
	September 30, 2012	 	$	1,190,100	 
	October 31, 2012	 	$	1,149,500	 
	November 30, 2012	 	$	1,139,600	 
	December 31, 2012	 	$	1,006,200	 

 

Beginning with December 1, 2012,
Bank and Borrower hereby agree that, on or before December 1st of each year during the term of this Agreement, Borrower shall
provide to Bank a fully-funded budget for the upcoming calendar year, and Bank shall use that budget to establish the maximum
Cash Burn amounts for the upcoming year, with such maximum amounts being incorporated herein by an amendment, which shall be
promptly executed by Bank and Borrower.

 

    	12.

    	 

    

 

6.8           Notice
of Inbound Licensors. Prior to entering into or becoming bound by any material inbound license or agreement, Borrower shall
provide written notice to Bank of the material terms of such license or agreement with a description of its likely impact on Borrower’s
business or financial condition. .

 

6.9           Further
Assurances. At any time and from time to time Borrower shall execute and deliver such further instruments and take such further
action as may reasonably be requested by Bank to effect the purposes of this Agreement.

 

7.           NEGATIVE
COVENANTS.

 

Borrower covenants and agrees that, so
long as any credit hereunder shall be available and until the outstanding Obligations are paid in full or for so long as Bank may
have any commitment to make any Credit Extensions, Borrower will not do any of the following without Bank’s prior written
consent, which shall not be unreasonably withheld:

 

7.1           Dispositions.
Convey, sell, lease, license, transfer or otherwise dispose of (collectively, to “Transfer”), or permit any of
its Subsidiaries to Transfer, all or any part of its business or property, or move cash balances on deposit with Bank to accounts
opened at another financial institution, other than Permitted Transfers.

 

7.2           Change
in Name, Location, Executive Office, or Executive Management; Change in Business; Change in Fiscal Year; Change in Control. Change
its name or the state of Borrower’s incorporation or relocate its chief executive office without 30 days prior written notification
to Bank; replace or suffer the departure of its chief executive officer or chief financial officer without delivering written notification
to Bank within 10 days following such event; fail to appoint an interim replacement or fill a vacancy in the position of chief
executive officer or chief financial officer for more than 30 consecutive days; suffer a change on its board of directors which
results in the failure of at least one partner of Harris & Harris Group or its Affiliates to serve as a voting member, or suffer
the resignation of one or more directors from its board of directors in anticipation of the Company’s insolvency, in either
case without the prior written consent of Bank which may be withheld in Bank’s sole discretion; take action to liquidate, wind
up, or otherwise cease to conduct business in the ordinary course; engage in any business, or permit any of its Subsidiaries to
engage in any business, other than or reasonably related or incidental to the businesses currently engaged in by Borrower; change
its fiscal year end; have a Change in Control.

 

    	13.

    	 

    

 

7.3           Mergers
or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business
organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit
any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person except where (a)
each of the following conditions is applicable: (i) the consideration paid in connection with such transactions (including assumption
of liabilities) does not in the aggregate exceed $250,000 during any fiscal year, (ii) no Event of Default has occurred and is
continuing or would exist after giving effect to such transactions, (iii) such transactions do not result in a Change in Control,
and (iv) Borrower is the surviving entity; or (b) the Obligations are repaid in full concurrently with the closing of any merger
or consolidation of Borrower in which Borrower is not the surviving entity; provided, however, that Borrower shall not, without
Bank’s prior written consent, enter into any binding contractual arrangement with any Person to facilitate a merger or acquisition
of Borrower; provided however, Borrower may enter into any such agreement without Bank’s prior written consent so long as (i) no
Event of Default exists when such agreement is entered into by Borrower, (ii) such agreement does not give such Person the right
to claim any fee, payment or damages from any parties, other than from Borrower or Borrower’s investors, in connection with a sale
of Borrower’s stock or assets pursuant to or resulting from an assignment for the benefit of creditors, an asset turnover to Borrower’s
creditors (including, without limitation, Bank), foreclosure, bankruptcy or similar liquidation, and (iii) Borrower notifies Bank
in advance of entering into such an agreement (provided, the failure to give such notification shall not be deemed a material breach
of this Agreement).

 

7.4           Indebtedness.
Create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other
than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any
Indebtedness, except Indebtedness to Bank.

 

7.5           Encumbrances.
Create, incur, assume or allow any Lien with respect to its property, or assign or otherwise convey any right to receive income,
including the sale of any Accounts, or permit any of its Subsidiaries so to do, except for Permitted Liens, or covenant to any
other Person (other than (i) the licensors of in-licensed property with respect to such property or (ii) the lessors of specific
equipment or lenders financing specific equipment with respect to such leased or financed equipment) that Borrower in the future
will refrain from creating, incurring, assuming or allowing any Lien with respect to any of Borrower’s property.

 

7.6           Distributions.
Pay any dividends or make any other distribution or payment on account of or in redemption, retirement or purchase of any capital
stock, except that Borrower may (i) repurchase the stock of former employees or consultants pursuant to stock repurchase agreements
as long as an Event of Default does not exist prior to such repurchase or would not exist after giving effect to such repurchase,
and (ii) repurchase the stock of former employees or consultants pursuant to stock repurchase agreements by the cancellation of
indebtedness owed by such former employees or consultants to Borrower regardless of whether an Event of Default exists.

 

7.7           Investments.
Directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do,
other than Permitted Investments, or maintain or invest any of its Investment Property with a Person other than Bank or Bank’s
Affiliates or permit any Subsidiary to do so unless such Person has entered into a control agreement with Bank, in form and substance
satisfactory to Bank, or suffer or permit any Subsidiary to be a party to, or be bound by, an agreement that restricts such Subsidiary
from paying dividends or otherwise distributing property to Borrower.

 

    	14.

    	 

    

 

7.8          Transactions
with Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower
except for transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are
no less favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person.

 

7.9          Subordinated
Debt. Make any payment in respect of any Subordinated Debt, or permit any of its Subsidiaries to make any such payment, except
in compliance with the terms of such Subordinated Debt, or amend any provision affecting Bank’s rights contained in any documentation
relating to the Subordinated Debt without Bank’s prior written consent.

 

7.10        Inventory
and Equipment. Store the Inventory or the Equipment of a book value in excess of $100,000 with a bailee, warehouseman, collocation
facility or similar third party unless the third party has been notified of Bank’s security interest and Bank (a) has received
an acknowledgment from the third party that it is holding or will hold the Inventory or Equipment for Bank’s benefit or (b)
is in possession of the warehouse receipt, where negotiable, covering such Inventory or Equipment. Except for Inventory sold in
the ordinary course of business and for movable items of personal property having an aggregate book value not in excess of $100,000,
and except for such other locations as Bank may approve in writing, Borrower shall keep the Inventory and Equipment only at the
location set forth in Section 10 and such other locations of which Borrower gives Bank prior written notice and as to which Bank
is able to take such actions as may be necessary to perfect its security interest or to obtain a bailee’s acknowledgment
of Bank’s rights in the Collateral.

 

7.11        No
Investment Company; Margin Regulation. Become or be controlled by an “investment company,” within the meaning of
the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business
of extending credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any Credit Extension for such
purpose.

 

8.           EVENTS
OF DEFAULT.

 

Any one or more
of the following events shall constitute an Event of Default by Borrower under this Agreement:

 

8.1          Payment
Default. If Borrower fails to pay any of the Obligations when due;

 

8.2          Covenant
Default.

 

(a)          If
Borrower fails to perform any obligation under Sections 6.2 (financial reporting), 6.4 (taxes), 6.5 (insurance), 6.6 (primary
accounts) or 6.7 (financial covenants), or violates any of the covenants contained in Article 7 of this Agreement; or

 

    	15.

    	 

    

 

(b)          If
Borrower fails or neglects to perform or observe any other material term, provision, condition, covenant contained in this Agreement,
in any of the Loan Documents, or in any other present or future agreement between Borrower and Bank and as to any default under
such other term, provision, condition or covenant that can be cured, has failed to cure such default within fifteen (15) days
after Borrower receives notice thereof or the Chief Executive Office or Chief Financial Officer of Borrower has actual knowledge
thereof; provided, however, that if the default cannot by its nature be cured within the fifteen (15) day period or cannot after
diligent attempts by Borrower be cured within such fifteen (15) day period, and such default is likely to be cured within a reasonable
time, then Borrower shall have an additional reasonable period (which shall not in any case exceed forty-five (45) days) to attempt
to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event
of Default but no Credit Extensions will be made.

 

8.3          Material
Adverse Change. If there occurs any circumstance or any circumstances which would reasonably be expected to have a Material
Adverse Effect;

 

8.4          Attachment.
If any material portion of Borrower’s assets is attached, seized, subjected to a writ or distress warrant, or is levied
upon, or comes into the possession of any trustee, receiver or person acting in a similar capacity and such attachment, seizure,
writ or distress warrant or levy has not been removed, discharged or rescinded within 10 days, or if Borrower is enjoined, restrained,
or in any way prevented by court order from continuing to conduct all or any material part of its business affairs, or if a judgment
or other claim becomes a lien or encumbrance upon any material portion of Borrower’s assets, or if a notice of lien, levy,
or assessment is filed of record with respect to any material portion of Borrower’s assets by the United States Government,
or any department, agency, or instrumentality thereof, or by any state, county, municipal, or governmental agency, and the same
is not paid within ten days after Borrower receives notice thereof, provided that none of the foregoing shall constitute an Event
of Default where such action or event is stayed or an adequate bond has been posted pending a good faith contest by Borrower (provided
that no Credit Extensions will be made during such cure period);

 

8.5          Insolvency.
If Borrower becomes insolvent, or if an Insolvency Proceeding is commenced by Borrower, or if an Insolvency Proceeding is commenced
against Borrower and is not dismissed or stayed within 45 days (provided that no Credit Extensions will be made prior to the dismissal
of such Insolvency Proceeding);

 

8.6          Other
Agreements. If there is a default by the Borrower in any agreement to which Borrower is a party with a third party or parties
resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in
an amount in excess of $250,000 or that would reasonably be expected to have a Material Adverse Effect;

 

8.7          Judgments.
If a final, uninsured judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at
least $250,000 shall be rendered against Borrower and shall remain unsatisfied and unstayed for a period of 10 days (provided that
no Credit Extensions will be made prior to the satisfaction or stay of the judgment); or

 

8.8          Misrepresentations.
If any material misrepresentation or material misstatement exists as of the date made in any warranty or representation set
forth herein or in any certificate delivered to Bank by any Responsible Officer pursuant to this Agreement or to induce Bank to
enter into this Agreement or any other Loan Document.

 

    	16.

    	 

    

  

9.           BANK’S
RIGHTS AND REMEDIES.

 

9.1          Rights
and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, at its election, without notice
of its election and without demand, do any one or more of the following, all of which are authorized by Borrower:

 

(a)          Declare
all Obligations, whether evidenced by this Agreement, by any of the other Loan Documents, or otherwise, immediately due and payable
(provided that upon the occurrence of an Event of Default described in Section 8.5 (insolvency), all Obligations shall become
immediately due and payable without any action by Bank);

 

(b)          Demand
that Borrower (i) deposit cash with Bank in an amount equal to the amount of any Letters of Credit remaining undrawn, as collateral
security for the repayment of any future drawings under such Letters of Credit, and (ii) pay in advance all Letter of Credit fees
scheduled to be paid or payable over the remaining term of the Letters of Credit, and Borrower shall promptly deposit and pay
such amounts;

 

(c)          Cease
advancing money or extending credit to or for the benefit of Borrower under this Agreement or under any other agreement between
Borrower and Bank;

 

(d)          Settle
or adjust disputes and claims directly with account debtors for amounts, upon terms and in whatever order that Bank reasonably
considers advisable;

 

(e)          Make
such payments and do such acts as Bank considers necessary or reasonable to protect its security interest in the Collateral. Borrower
agrees to assemble the Collateral if Bank so requires, and to make the Collateral available to Bank as Bank may designate. Borrower
authorizes Bank to enter the premises where the Collateral is located, to take and maintain possession of the Collateral, or any
part of it, and to pay, purchase, contest, or compromise any encumbrance, charge, or lien which in Bank’s determination
appears to be prior or superior to its security interest and to pay all expenses incurred in connection therewith. With respect
to any of Borrower’s owned premises, Borrower hereby grants Bank a license to enter into possession of such premises and
to occupy the same, without charge, in order to exercise any of Bank’s rights or remedies provided herein, at law, in equity,
or otherwise;

 

(f)          Set
off and apply to the Obligations any and all (i) balances and deposits of Borrower held by Bank, and (ii) indebtedness at any
time owing to or for the credit or the account of Borrower held by Bank;

 

(g)          Ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell (in the manner provided for
herein) the Collateral. Bank is hereby granted a license or other right, to the extent it may be granted, solely pursuant to the
provisions of this Section 9.1, to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any name,
trade secrets, trade names, trademarks, service marks, and advertising matter, or any property of a similar nature, to complete
production of, advertise for sale, and sell any Collateral and, in connection with Bank’s exercise of its rights under this
Section 9.1, Borrower’s rights under all licenses which are included in the Collateral and all franchise agreements shall
inure to Bank’s benefit;

 

    	17.

    	 

    

  

(h)          Sell
the Collateral at either a public or private sale, or both, by way of one or more contracts or transactions, for cash or on terms,
in such manner and at such places (including Borrower’s premises) as Bank determines is commercially reasonable, and apply
any proceeds to the Obligations in whatever manner or order Bank deems appropriate. Bank may sell the Collateral without giving
any warranties as to the Collateral. Bank may specifically disclaim any warranties of title or the like. This procedure will not
be considered adversely to affect the commercial reasonableness of any sale of the Collateral. If Bank sells any of the Collateral
upon credit, Borrower will be credited only with payments actually made by the purchaser, received by Bank, and applied to the
indebtedness of the purchaser. If the purchaser fails to pay for the Collateral, Bank may resell the Collateral and Borrower shall
be credited with the proceeds of the sale;

 

(i)          Bank
may credit bid and purchase at any public sale;

 

(j)          Apply
for the appointment of a receiver, trustee, liquidator or conservator of the Collateral, without notice and without regard to
the adequacy of the security for the Obligations and without regard to the solvency of Borrower, any guarantor or any other Person
liable for any of the Obligations; and

 

(k)          Any
deficiency that exists after disposition of the Collateral as provided above will be paid immediately by Borrower.

 

Bank may comply
with any applicable state or federal law requirements in connection with a disposition of the Collateral and compliance will not
be considered adversely to affect the commercial reasonableness of any sale of the Collateral.

 

9.2          Power
of Attorney. Effective only upon the occurrence and during the continuance of an Event of Default, Borrower hereby irrevocably
appoints Bank (and any of Bank’s designated officers, or employees) as Borrower’s true and lawful attorney to: (a)
send requests for verification of Accounts or notify account debtors of Bank’s security interest in the Accounts; (b) endorse
Borrower’s name on any checks or other forms of payment or security that may come into Bank’s possession; (c) sign
Borrower’s name on any invoice or bill of lading relating to any Account, drafts against account debtors, schedules and assignments
of Accounts, verifications of Accounts, and notices to account debtors; (d) dispose of any Collateral; (e) make, settle, and adjust
all claims under and decisions with respect to Borrower’s policies of insurance; (f) settle and adjust disputes and claims
respecting the accounts directly with account debtors, for amounts and upon terms which Bank determines to be reasonable; and (g)
file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral;
provided Bank may exercise such power of attorney to sign the name of Borrower on any of the documents described in clause (g)
above, regardless of whether an Event of Default has occurred. The appointment of Bank as Borrower’s attorney in fact, and
each and every one of Bank’s rights and powers, being coupled with an interest, is irrevocable until all of the Obligations
have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated.

 

    	18.

    	 

    

 

9.3           Accounts
Collection. At any time after the occurrence and during the continuation of an Event of Default, Bank may notify any Person
owing funds to Borrower of Bank’s security interest in such funds and verify the amount of such Account. Borrower shall collect
all amounts owing to Borrower for Bank, receive in trust all payments as Bank’s trustee, and immediately deliver such payments
to Bank in their original form as received from the account debtor, with proper endorsements for deposit.

 

9.4           Bank
Expenses. If Borrower fails to pay any amounts or furnish any required proof of payment due to third persons or entities, as
required under the terms of this Agreement, then Bank may do any or all of the following after reasonable notice to Borrower: (a)
make payment of the same or any part thereof; and/or (b) obtain and maintain insurance policies of the type discussed in Section
6.5 of this Agreement, and take any action with respect to such policies as Bank deems prudent. Any amounts so paid or deposited
by Bank shall constitute Bank Expenses, shall be immediately due and payable, and shall bear interest at the then applicable rate
hereinabove provided, and shall be secured by the Collateral. Any payments made by Bank shall not constitute an agreement by Bank
to make similar payments in the future or a waiver by Bank of any Event of Default under this Agreement.

 

9.5           Bank’s
Liability for Collateral. Bank has no obligation to clean up or otherwise prepare the Collateral for sale. All risk of loss,
damage or destruction of the Collateral shall be borne by Borrower.

 

9.6           No
Obligation to Pursue Others. Bank has no obligation to attempt to satisfy the Obligations by collecting them from any other
person liable for them and Bank may release, modify or waive any collateral provided by any other Person to secure any of the Obligations,
all without affecting Bank’s rights against Borrower. Borrower waives any right it may have to require Bank to pursue any
other Person for any of the Obligations.

 

9.7           Remedies
Cumulative. Bank’s rights and remedies under this Agreement, the Loan Documents, and all other agreements shall be cumulative.
Bank shall have all other rights and remedies not inconsistent herewith as provided under the Code, by law, or in equity. No exercise
by Bank of one right or remedy shall be deemed an election, and no waiver by Bank of any Event of Default on Borrower’s part
shall be deemed a continuing waiver. No delay by Bank shall constitute a waiver, election, or acquiescence by it. No waiver by
Bank shall be effective unless made in a written document signed on behalf of Bank and then shall be effective only in the specific
instance and for the specific purpose for which it was given. Borrower expressly agrees that this Section 9.7 may not be waived
or modified by Bank by course of performance, conduct, estoppel or otherwise.

 

9.8           Demand;
Protest. Except as otherwise provided in this Agreement, Borrower waives demand, protest, notice of protest, notice of default
or dishonor, notice of payment and nonpayment and any other notices relating to the Obligations.

 

    	19.

    	 

    

 

10.         NOTICES.

 

Unless otherwise provided in this Agreement,
all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall
be in writing and (except for financial statements and other informational documents which may be sent by first-class mail, postage
prepaid) shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return
receipt requested, or by telefacsimile to Borrower or to Bank, as the case may be, at its addresses set forth below:

 

	If to Borrower:	Enumeral Biomedical Corp.
	 	1450 Broadway
	 	New York, NY 10018

 

	 	Attn:	 	 
	 	FAX:	 	 

 

	If to Bank:	Square 1 Bank
	 	406 Blackwell Street, Suite 240 
	 	Durham, North Carolina 27701 
	 	Attn: Loan Operations Manager 
	 	FAX: (919) 314-3080

 

	with a copy to:	Square 1 Bank
	 	424 Madison Avenue, Sixth Floor 
	 	New York, NY 10017
	 	 
	 	Attn: Bill Stickle 
	 	FAX: (646)336-4961

 

The parties hereto may change the address
at which they are to receive notices hereunder, by notice in writing in the foregoing manner given to the other.

 

    	20.

    	 

    

  

11.        CHOICE
OF LAW AND VENUE; JURY TRIAL WAIVER.

 

This Agreement shall be governed by,
and construed in accordance with, the internal laws of the State of North Carolina, without regard to principles of conflicts of
law. Jurisdiction shall lie in the State of North Carolina. All disputes, controversies, claims, actions and similar proceedings
arising with respect to Borrower’s account or any related agreement or transaction shall be brought in the General Court
of Justice of North Carolina sitting in Durham County, North Carolina or the United States District Court for the Middle District
of North Carolina, except as provided below with respect to arbitration of such matters. BANK AND BORROWER EACH ACKNOWLEDGE THAT
THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH OF THEM, AFTER CONSULTING OR HAVING HAD THE
OPPORTUNITY TO CONSULT, WITH COUNSEL OF THEIR CHOICE, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT ANY OF THEM MAY
HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR LOAN DOCUMENT
OR ANY OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN),
OR ACTION OF ANY OF THEM. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN MODIFIED IN ANY RESPECT OR RELINQUISHED BY BANK OR
BORROWER, EXCEPT BY A WRITTEN INSTRUMENT EXECUTED BY EACH OF THEM. If the jury waiver set forth in this Section 11 is not enforceable,
then any dispute, controversy, claim, action or similar proceeding arising out of or relating to this Agreement, the Loan Documents
or any of the transactions contemplated therein shall be settled by final and binding arbitration held in Durham County, North
Carolina in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association by one arbitrator
appointed in accordance with those rules. The arbitrator shall apply North Carolina law to the resolution of any dispute, without
reference to rules of conflicts of law or rules of statutory arbitration. Judgment upon any award resulting from arbitration may
be entered into and enforced by any state or federal court having jurisdiction thereof. Notwithstanding the foregoing, the parties
may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance
with this Section. The costs and expenses of the arbitration, including without limitation, the arbitrator’s fees and expert
witness fees, and reasonable attorneys’ fees, incurred by the parties to the arbitration may be awarded to the prevailing
party, in the discretion of the arbitrator, or may be apportioned between the parties in any manner deemed appropriate by the arbitrator.
Unless and until the arbitrator decides that one party is to pay for all (or a share) of such costs and expenses, both parties
shall share equally in the payment of the arbitrator’s fees as and when billed by the arbitrator.

 

12.         GENERAL
PROVISIONS.

 

12.1         Successors
and Assigns. This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each
of the parties and shall bind all persons who become bound as a debtor to this Agreement; provided, however, that neither this
Agreement nor any rights hereunder may be assigned by Borrower without Bank’s prior written consent, which consent may be
granted or withheld in Bank’s sole discretion. Bank shall have the right without the consent of or notice to Borrower to
sell, assign, transfer, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations,
rights and benefits hereunder.

 

12.2         Indemnification.
Borrower shall defend, indemnify and hold harmless Bank and its officers, employees, and agents against: (a) all obligations,
demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this
Agreement; and (b) all losses or Bank Expenses in any way suffered, incurred, or paid by Bank, its officers, employees and agents
as a result of or in any way arising out of, following, or consequential to transactions between Bank and Borrower whether under
this Agreement, or otherwise (including without limitation reasonable attorneys fees and expenses), except for losses caused by
Bank’s gross negligence or willful misconduct.

 

12.3         Time
of Essence. Time is of the essence for the performance of all obligations set forth in this Agreement.

 

    	21.

    	 

    

  

12.4         Severability
of Provisions. Each provision of this Agreement shall be severable from every other provision of this Agreement for the purpose
of determining the legal enforceability of any specific provision.

 

12.5         Amendments
in Writing, Integration. All amendments to or terminations of this Agreement or the other Loan Documents must be in
writing. All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect
to the subject matter of this Agreement and the other Loan Documents, if any, are merged into this Agreement and the Loan Documents.

 

12.26         Counterparts.
This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one
and the same Agreement. Executed copies of the signature pages of this Agreement sent by facsimile or transmitted electronically
in Portable Document Format (“PDF”), or any similar format, shall be treated as originals, fully binding and with full
legal force and effect, and the parties waive any rights they may have to object to such treatment.

 

12.7         Survival.
All covenants, representations and warranties made in this Agreement shall continue in full force and effect so long as any
Obligations remain outstanding or Bank has any obligation to make any Credit Extension to Borrower. The obligations of Borrower
to indemnify Bank with respect to the expenses, damages, losses, costs and liabilities described in Section 12.2 shall survive
until all applicable statute of limitations periods with respect to actions that may be brought against Bank have run.

 

12.8         Confidentiality.
In handling any confidential information, Bank and all employees and agents of Bank shall exercise the same degree of care
that Bank exercises with respect to its own proprietary information of the same types to maintain the confidentiality of any non-public
information thereby received or received pursuant to this Agreement except that disclosure of such information may be made (i)
to the subsidiaries or Affiliates of Bank or Borrower in connection with their present or prospective business relations with Borrower,
(ii) to prospective transferees or purchasers of any interest in the Credit Extensions, provided that they have entered into a
comparable confidentiality agreement in favor of Borrower and have delivered a copy to Borrower, (iii) as required by law, regulations,
rule or order, subpoena, judicial order or similar order, (iv) as may be required in connection with the examination, audit or
similar investigation of Bank and (v) as Bank may determine in connection with the enforcement of any remedies hereunder. Confidential
information hereunder shall not include information that either: (a) is in the public domain or in the knowledge or possession
of Bank when disclosed to Bank, or becomes part of the public domain after disclosure to Bank through no fault of Bank; or (b)
is disclosed to Bank by a third party, provided Bank does not have actual knowledge that such third party is prohibited from disclosing
such information.

 

********

 

    	22.

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first above written.

 

	 	ENUMERAL BIOMEDICAL CORP.
	 	 	 
	 	By:	/s/ John J. Rydzewski
	 	 	 
	 	Title:	Executive Chairman
	 	 	 
	 	SQUARE 1 BANK
	 	 	 
	 	By:	/s/ Basil Kushuir
	 	 	 
	 	Title:	AVP

 

    	23.

    	 

    

 

EXHIBIT A

 

DEFINITIONS

 

“Accounts” means all presently
existing and hereafter arising accounts, contract rights, payment intangibles and all other forms of obligations owing to Borrower
arising out of the sale or lease of goods (including, without limitation, the licensing of software and other technology) or the
rendering of services by Borrower and any and all credit insurance, guaranties, and other security therefore, as well as all merchandise
returned to or reclaimed by Borrower and Borrower’s Books relating to any of the foregoing.

 

“Affiliate” means, with
respect to any Person, any Person that owns or controls directly or indirectly such Person, any Person that controls or is controlled
by or is under common control with such Person, and each of such Person’s senior executive officers, directors, and general
partners.

 

“Authorized Officer” means
someone designated as such in the corporate resolution provided by Borrower to Bank in which this Agreement and the transactions
contemplated hereunder are authorized by Borrower’s board of directors. If Borrower provides subsequent corporate resolutions
to Bank after the Closing Date, the individual(s) designated as “Authorized Officer(s)” in the most-recently provided
resolution shall be the only “Authorized Officers” for purposes of this Agreement.

 

“Bank Expenses” means all
reasonable costs or expenses (including reasonable attorneys’ fees and expenses) incurred in connection with the preparation,
negotiation, administration, and enforcement of the Loan Documents; reasonable Collateral audit fees; and Bank’s reasonable
attorneys’ fees and expenses (whether generated in-house or by outside counsel) incurred in amending, enforcing or defending
the Loan Documents (including fees and expenses of appeal), incurred before, during and after an Insolvency Proceeding, whether
or not suit is brought.

 

“Borrower’s
Books” means all of Borrower’s books and records including: ledgers; records concerning Borrower’s assets
or liabilities, the Collateral, business operations or financial condition; and all computer programs, or tape files, and the
equipment, containing such information.

 

“Business Day” means any
day that is not a Saturday, Sunday, or other day on which banks in the State of North Carolina are authorized or required to close.

 

“Cash” means unrestricted
cash and cash equivalents.

 

“Cash Bum” means an amount
equal to the prior period’s Cash minus the current period’s ending Cash that has been adjusted for any changes to Cash
as a result of borrowings and repayments of borrowings, proceeds from the sale of equity for Cash and the exercise of stock options
or warrants for Cash, paid-in-capital and minority interest, and capital expenditures financed under a capital lease.

 

“Change in Control” shall
mean a transaction other than a bona fide equity financing or series of financings on terms and from investors reasonably acceptable
to Bank in which any “person” or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Securities
Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of
1934), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of Borrower ordinarily
entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority
of the Board of Directors of Borrower, who did not have such power before such transaction.

 

    	1.

    	 

    

 

“Closing Date” means the
date of this Agreement.

 

“Code” means the North Carolina
Uniform Commercial Code as amended or supplemented from time to time.

 

“Collateral” means the property
described on Exhibit B attached hereto and all Negotiable Collateral to the extent not described on Exhibit B, except to the extent
any such property (i) is nonassignable by its terms without the consent of the licensor thereof or another party (but only to the
extent such prohibition on transfer is enforceable under applicable law, including, without limitation, §25-9-406 and §25-9-408
of the Code), (ii) the granting of a security interest therein is contrary to applicable law, provided that upon the cessation
of any such restriction or prohibition, such property shall automatically become part of the Collateral, (iii) constitutes the
capital stock of a controlled foreign corporation (as defined in the IRC), in excess of 65% of the voting power of all classes
of capital stock of such controlled foreign corporations entitled to vote, or (iv) property (including any attachments, accessions
or replacements) that is subject to a Lien that is permitted pursuant to clause (c) of the definition of Permitted Liens, if the
grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement creating
such Permitted Lien or would otherwise constitute a default thereunder, provided, that such property will be deemed “Collateral”
hereunder upon the termination and release of such Permitted Lien.

 

“Collateral State” means
the state or states where the Collateral is located, which is New York and Massachusetts.

 

“Contingent Obligation”
means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i)
any indebtedness, lease, dividend, letter of credit or other obligation of another, including, without limitation, any such obligation
directly or indirectly guaranteed, endorsed, comade or discounted or sold with recourse by that Person, or in respect of which
that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate
credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate,
currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement
designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however,
that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course
of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of
the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably
anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall
not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.

 

“Copyrights” means any and
all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative
work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing,
created, acquired or held.

 

“Credit Extension” means
each Term Loan, Equipment Advance, or any other extension of credit, by Bank to or for the benefit of Borrower hereunder.

 

“Equipment” means all present
and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools, parts and attachments in which Borrower
has any interest.

 

“Equipment Advance(s)” means
a cash advance or cash advances under the Equipment Loan.

 

    	2.

    	 

    

  

“Equipment Availability End Date”
means July 31, 2012.

 

“Equipment Interest-Only End Date”
means, for each Equipment Advance, the date that is 6 months after the date upon which that particular Equipment Advance is made.

 

“Equipment Loan” means a
Credit Extension of up to $790,000.

 

“Equipment Maturity Date”
means, for each Equipment Advance, the date that is 36 months after the date upon which that particular Equipment Advance is made.

 

“ERISA” means the Employee
Retirement Income Security Act of 1974, as amended, and the regulations thereunder.

 

“Event of Default” has the
meaning assigned in Article 8.

 

“GAAP” means generally accepted
accounting principles, consistently applied, as in effect from time to time in the United States.

 

“Indebtedness” means (a)
all indebtedness for borrowed money or the deferred purchase price of property or services, including without limitation reimbursement
and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures
or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations, including but not limited to any
sublimit contained herein.

 

“Insolvency Proceeding”
means any proceeding commenced by or against any Person or entity under any provision of the United States Bankruptcy Code, as
amended, or under any other bankruptcy or insolvency law, including assignments for the benefit of creditors, formal or informal
moratoria, compositions, extension generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

 

“Inventory” means all present
and future inventory in which Borrower has any interest.

 

“Investment” means any beneficial
ownership of (including stock, partnership or limited liability company interest or other securities) any Person, or any loan,
advance or capital contribution to any Person.

 

“Investment Agreement” means,
collectively, Borrower’s stock purchase and other agreement(s) pursuant to which Borrower most recently issued its preferred
stock.

 

“IRC” means the Internal
Revenue Code of 1986, as amended, and the regulations thereunder.

 

“Letter of Credit” means
a commercial or standby letter of credit or similar undertaking issued by Bank at Borrower’s request.

 

“Lien” means any mortgage,
lien, deed of trust, charge, pledge, security interest or other encumbrance.

 

“Liquidity” means unrestricted Cash in
Bank.

 

“Liquidity Ratio” means
the ratio of Liquidity to all Indebtedness to Bank.

 

“Loan Documents” means,
collectively, this Agreement, any note or notes executed by Borrower, and any other document, instrument or agreement entered into
in connection with this Agreement, all as amended or extended from time to time.

 

    	3.

    	 

    

  

“Material Adverse Effect”
means a material adverse effect on: (i) the operations, business or financial condition of Borrower and its Subsidiaries taken
as a whole; (ii) the ability of Borrower to repay the Obligations or otherwise perform its obligations under the Loan Documents;
or (iii) Borrower’s interest in, or the value, perfection or priority of Bank’s security interest in the Collateral.

 

“Negotiable Collateral”
means all of Borrower’s present and future letters of credit of which it is a beneficiary, drafts, instruments (including
promissory notes), securities, documents of title, and chattel paper, and Borrower’s Books relating to any of the foregoing.

 

“New Equity” means cash
proceeds of at least Two Million Dollars ($2,000,000) received by Borrower after the Closing Date from the sale or issuance of
Borrower’s equity securities to investors acceptable to Bank.

 

“Obligations” means all
debt, principal, interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this Agreement or any other agreement,
whether absolute or contingent, due or to become due, now existing or hereafter arising, including any interest that accrues after
the commencement of an Insolvency Proceeding and including any debt, liability, or obligation owing from Borrower to others that
Bank may have obtained by assignment or otherwise.

 

“Patents” means all patents,
patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues,
extensions and continuations-in-part of the same.

 

“Periodic Payments” means
all installments or similar recurring payments that Borrower may now or hereafter become obligated to pay to Bank pursuant to the
terms and provisions of any instrument, or agreement now or hereafter in existence between Borrower and Bank.

 

“Permitted Indebtedness”
means:

 

(a)          Indebtedness
of Borrower in favor of Bank arising under this Agreement or any other Loan Document;

 

(b)          Indebtedness
existing on the Closing Date and disclosed in the Schedule;

 

(c)          Indebtedness
not to exceed $125,000 in the aggregate in any fiscal year of Borrower secured by a lien described in clause (c) of the defined
term “Permitted Liens,” provided such Indebtedness does not exceed at the time it is incurred the lesser of the cost
or fair market value of the property financed with such Indebtedness;

 

(d)          Subordinated
Debt;

 

(e)          Indebtedness
to trade creditors incurred in the ordinary course of business; and

 

(f)          Extensions,
refinancing and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms
modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be.

 

“Permitted Investment” means:

 

(a)          Investments
existing on the Closing Date disclosed in the Schedule;

 

    	4.

    	 

    

 

(b)          (i)
Marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof
maturing within one year from the date of acquisition thereof, (ii) commercial paper maturing no more than one year from the date
of creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s
Investors Service, (iii) Bank’s certificates of deposit maturing no more than one year from the date of investment therein,
and (iv) Bank’s money market accounts; (v) Investments in regular deposit or checking accounts held with Bank or subject
to a control agreement in favor of Bank; and (vi) Investments consistent with any investment policy adopted by the Borrower’s
board of directors;

 

(c)          Repurchases
of stock from former employees or directors of Borrower under the terms of applicable repurchase agreements (i) in an aggregate
amount not to exceed $125,000 in any fiscal year, provided that no Event of Default has occurred and, is continuing or would exist
after giving effect to the repurchases, or (ii) in any amount where the consideration for the repurchase is the cancellation of
indebtedness owed by such former employees to Borrower regardless of whether an Event of Default exists;

 

(d)          Investments
accepted in connection with Permitted Transfers;

 

(e)          Investments
of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed $125,000 in the
aggregate in any fiscal year;

 

(f)          Investments
not to exceed $125,000 outstanding in the aggregate at any time consisting of (i) travel advances and employee relocation loans
and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating
to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plan agreements approved
by Borrower’s Board of Directors;

 

(g)          Investments
in unfinanced capital expenditures in any fiscal year, not to exceed $250,000;

 

(h)          Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s
business;

 

(i)          Investments
consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates,
in the ordinary course of business, provided that this subparagraph (h) shall not apply to Investments of Borrower in any Subsidiary;

 

(j)          Joint
ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the licensing of
technology, the development of technology or the providing of technical support, provided that any cash Investments by
Borrower do not exceed $125,000 in the aggregate in any fiscal year; and

 

(k)          Investments
permitted under Section 7.3.

 

“Permitted Liens” means
the following:

 

(a)          Any
Liens existing on the Closing Date and disclosed in the Schedule (excluding Liens to be satisfied with the proceeds of the Credit
Extensions) or arising under this Agreement, the other Loan Documents, or any other agreement in favor of Bank;

 

(b)          Liens
for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by
appropriate proceedings and for which Borrower maintains adequate reserves;

 

    	5.

    	 

    

 

(c)          Liens
not to exceed $125,000 in the aggregate (i) upon or in any Equipment (other than Equipment financed by a Credit Extension) acquired
or held by Borrower or any of its Subsidiaries to secure the purchase price of such Equipment or indebtedness incurred solely
for the purpose of financing the acquisition or lease of such Equipment, or (ii) existing on such Equipment at the time of its
acquisition, in each case provided that the Lien is confined solely to the property so acquired and improvements thereon, and
the proceeds of such Equipment;

 

(d)          Liens
incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in
clauses (a) through (c) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered
by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced does not increase;

 

(e)          Liens
arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Sections 8.4 (attachment)
or 8.7 (judgments);

 

(f)          Liens
securing Subordinated Debt; and

 

(g)          inchoate
materialmen’s, mechanics, repairmen’s and similar liens arising by operation of law in the ordinary course of business
for amounts not to exceed $125,000 which are not delinquent.

 

“Permitted Transfer” means
the conveyance, sale, lease, transfer or disposition by Borrower or any Subsidiary of:

 

(a)          Inventory
in the ordinary course of business;

 

(b)          licenses
and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business;

 

(c)          worn-out,
damaged, surplus or obsolete Equipment not financed with the proceeds of Credit Extensions or if financed with the proceeds of
a Credit Extension provided the Company replaces such Equipment with Equipment of equivalent value;

 

(d)          grants
of security interests and other Liens that constitute Permitted Liens; and

 

(e)          other
assets of Borrower or its Subsidiaries that do not in the aggregate exceed $125,000 during any fiscal year.

 

“Person” means any individual,
sole proprietorship, partnership, limited liability company, joint venture, trust, unincorporated organization, association, corporation,
institution, public benefit corporation, firm, joint stock company, estate, entity or governmental agency.

 

“Prime Rate” means the variable
rate of interest, per annum, most recently announced by Bank, as its “prime rate,” whether or not such announced rate
is the lowest rate available from Bank.

 

“Responsible Officer” means
each of the Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer, Vice President of Finance and the
Controller of Borrower, as well as any other officer or employee identified in as an Authorized Officer in the corporate resolution
delivered by Borrower to Bank in connection with this Agreement.

 

    	6.

    	 

    

  

“Schedule” means the schedule
of exceptions attached hereto and approved by Bank, if any.

 

“Soft Costs” means taxes,
shipping, warranty charges, freight discounts and installation expense.

 

“SOS Reports” means the
official reports from the Secretaries of State of each Collateral State, the state where Borrower’s chief executive office
is located, the state of Borrower’s formation and other applicable federal, state or local government offices identifying
all current security interests filed in the Collateral and Liens of record as of the date of such report.

 

“Subordinated Debt” means
any debt incurred by Borrower that is subordinated in writing to the debt owing by Borrower to Bank on terms reasonably acceptable
to Bank (and identified as being such by Borrower and Bank).

 

“Subsidiary” means any corporation,
partnership or limited liability company or joint venture in which (i) any general partnership interest or (ii) more than 50% of
the stock, limited liability company interest or joint venture of which by the terms thereof ordinary voting power to elect the
Board of Directors, managers or trustees of the entity, at the time as of which any determination is being made, is owned by Borrower,
either directly or through an Affiliate.

 

“Term Loan A Amount” means
Five Hundred Thousand Dollars $500,000.

 

“Term Loan A Availability End
Date” means the Closing Date.

 

“Term Loan A Interest-Only End
Date” means June 1, 2012.

 

“Term Loan A Maturity Date”
means December 1, 2014.

 

“Term Loan B Amount” means
Zero Dollars ($0.00); provided however, that if Borrower delivers evidence to Bank that Borrower has received the New Equity in
its entirety, “Term Loan B Amount” shall there after mean Five Hundred Thousand Dollars ($500,000).

 

“Term Loan B Availability End
Date” means July 31, 2012.

 

“Term Loan B Interest-Only End
Date” means the date that is 6 months after the date upon which Term Loan B is made.

 

“Term Loan B Maturity Date”
means the date that is 36 months after the date upon which Term Loan B is made.

 

“Trademarks” means any trademark
and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections,
and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.

 

    	7.

    	 

    

 

 

	DEBTOR:	ENUMERAL BIOMEDICAL CORP.
	 	 
	SECURED PARTY:	SQUARE 1 BANK

 

EXHIBIT B

 

COLLATERAL DESCRIPTION ATTACHMENT TO LOAN AND SECURITY
AGREEMENT

 

All personal property of Borrower (herein referred to as “Borrower”
or “Debtor”) whether presently existing or hereafter created or acquired, and wherever located, including, but not
limited to:

 

(a)          all
accounts (including health-care-insurance receivables), chattel paper (including tangible and electronic chattel paper), deposit
accounts, documents (including negotiable documents), equipment (including all accessions and additions thereto), financial assets,
general intangibles (including patents, trademarks, copyrights, goodwill, payment intangibles, domain names, and software) goods
(including fixtures), instruments (including promissory notes), inventory (including all goods held for sale or lease or to be
furnished under a contract of service, and including returns and repossessions), investment property (including securities and
securities entitlements), letter of credit rights, money, and all of Debtor’s books and records with respect to any of the
foregoing, and the computers and equipment containing said books and records;

 

(b)          any
and all cash proceeds and/or noncash proceeds of any of the foregoing, including, without limitation, insurance proceeds, and
all supporting obligations and the security therefor or for any right to payment. All terms above have the meanings given to them
in the North Carolina Uniform Commercial Code, as amended or supplemented from time to time, including revised Division 9 of the
Uniform Commercial Code-Secured Transactions.

 

Notwithstanding the foregoing (including, without
limitation, any language in clause (a) above), the Collateral shall not include any of the intellectual property, in any medium,
of any kind or nature whatsoever, now or hereafter owned or acquired or received by Borrower, or in which Borrower now holds or
hereafter acquires or receives any right or interest (collectively, the “Intellectual Property”); provided, however,
that the Collateral shall include all accounts and general intangibles that consist of rights to payment and proceeds from the
sale, licensing or disposition of all or any part, or rights in, the foregoing (the “Rights to Payment”).

 

Notwithstanding the foregoing, if a judicial authority (including
a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security
interest in the Rights to Payment, then the Collateral shall automatically, and effective as of December 1, 2011, include the Intellectual
Property to the extent and only to the extent necessary to permit perfection of Bank’s security interest in the Rights to
Payment, and further provided, however, that Bank’s enforcement rights with respect to any security interest in the Intellectual
Property shall be absolutely limited to the Rights to Payment only, and Bank shall have no recourse whatsoever with respect to
the underlying Intellectual Property.

 

    	1.

    	 

    

 

EXHIBIT C

 

LOAN ADVANCE/PAYDOWN
REQUEST FORM

 

[Please refer to New Borrower Kit]

 

 

 

EXHIBIT D

COMPLIANCE CERTIFICATE

 

[Please refer to New Borrower Kit]

 

    	1.

    	 

    

 

SCHEDULE OF EXCEPTIONS

 

Permitted Indebtedness (Exhibit A) – None.

 

Permitted Investments (Exhibit A) –
None.

 

Permitted Liens (Exhibit A) – None.

 

Prior Names (Section 5.5) – Enumeral Technologies, Inc.

 

Litigation (Section 5.6) – None.

 

Inbound Licenses (Section 5.12) – Exclusive License Agreement,
as may be amended from time to time, between the Company and MIT (as amended from time to time, “MIT License”). This
MIT License is not assignable and therefore is excluded from the Collateral securing the loans hereunder.

 

    	1.

    	 

    

 

FIRST AMENDMENT

TO

LOAN AND SECURITY
AGREEMENT

 

This First Amendment
to Loan and Security Agreement (the “Amendment”), is entered into as of June 12, 2012, by and between
SQUARE 1 BANK (the ‘'Bank”) and ENUMERAL BIOMEDICAL CORP. (the “Borrower”).

 

RECITALS

 

Borrower and Bank are parties
to that Loan and Security Agreement dated as of December 5, 2011 (as amended from time to time, the “Agreement”).
The parties desire to amend the Agreement in accordance with the terms of this Amendment.

 

NOW, THEREFORE, the parties agree as follows:

 

		1)	A new Section 2.5(d) is hereby added to the Agreement, as follows:

 

(d)          Success
Fee. On July 5, 2015 or such earlier date as all of the outstanding Obligations hereunder are repaid in full, a fee equal
to $15,000, which shall be nonrefundable. This Section 2.5(d) shall survive any termination of this Agreement.

 

	 	2)	The first paragraph of Section 6.2 of the
Agreement is hereby amended and restated, as follows:

 

6.2          Financial
Statements, Reports, Certificates. Borrower shall deliver to Bank: (i) as soon as available, but in any event within 30
days after the end of each calendar month, a company prepared consolidated and consolidating balance sheet, cash flow
statement and income statement covering Borrower’s operations during such period, in a form reasonably acceptable to
Bank and certified by a Responsible Officer; (ii) as soon as available, but in any event within 180 days after the end of
Borrower’s fiscal year, audited (or such other level as is required by the Investment Agreement) consolidated and
consolidating financial statements of Borrower prepared in accordance with GAAP, consistently applied, together with an
opinion on such financial statements of an independent certified public accounting firm reasonably acceptable to Bank which
is either unqualified or qualified only for going concern, so long as in the case of the qualified opinion it is either
consented to in writing by Bank or in the alternative if following the delivery of such financial statements the Bank does
not consent to such qualified Borrower’s investors will provide additional equity as needed within 30 days after notice
from the Bank of such non consent to the qualified financial statements or otherwise; provided however, that the audited
consolidated and consolidating financial statements of Borrower for fiscal years 2011 and 2012 shall be delivered to Bank on
or before July 1, 2013, (iii) annual budget approved by Borrower’s Board of Directors as soon as available but not
later than 30 days before the beginning of the applicable calendar year, provided however, that for the 2012 annual budget
only, Borrower shall provide the 2012 annual budget approved by Borrower’s Board of Directors as soon as available but
not later than March 1, 2012; (iv) if applicable, copies of all statements, reports and notices sent or made available
generally by Borrower to its security holders or to any holders of Subordinated Debt and all reports on Forms 10-K and 10-Q
filed with the Securities and Exchange Commission; (v) promptly upon receipt of notice thereof, a report of any legal actions
pending or threatened against Borrower or any Subsidiary that could reasonably be expected to result in damages or costs to
Borrower or any Subsidiary of $250,000 or more; (vi) promptly upon receipt, each management letter prepared by
Borrower’s independent certified public accounting firm regarding Borrower’s management control systems, (vii)
such budgets, sales projections, operating plans or other financial information generally prepared by Borrower in the
ordinary course of business as Bank may reasonably request from time to time.

 

Enumeral Biomedical Corp. – 1st Amendment to
LSA

 

    	1

    	 

    

 

		3)	Section 6.7(b) of the Agreement is hereby amended and restated, as follows:

 

(b)          Cash
Burn. Tested monthly and calculated on a trailing six-months average, a Cash Burn of not more than the amounts shown in column
B below for the corresponding reporting period in column A.

 

	A	 	B	 
	Reporting Period Ending On	 	 	Maximum
                                         Cash Burn	 
	April 30, 2012	 	$	1,699,300	 
	May 31, 2012	 	$	1,658,900	 
	June 30, 2012	 	$	1,584,100	 
	July 31, 2012	 	$	2,020,729	 
	August 31, 2012	 	$	2,149,201	 
	September 30, 2012	 	$	1,997,476	 
	October 31, 2012	 	$	2,021,432	 
	November 30, 2012	 	$	2,079,360	 
	December 31, 2012	 	$	1,746,866	 

 

Beginning with December 1, 2012, Bank and Borrower hereby agree
that, on or before December 1st of each year during the term of this Agreement, Borrower shall provide to Bank a fully-funded budget
for the upcoming calendar year, and Bank shall use that budget to establish the maximum Cash Burn amounts for the upcoming year,
with such maximum amounts being incorporated herein by an amendment, which shall be promptly executed by Bank and Borrower.

 

	 	4)	The following definitions in Exhibit A to the Agreement are hereby amended and restated, as follows:

 

“Equipment Availability End Date”
December 5, 2012.

 

“Equipment Interest-Only End Date”
means December 5, 2012.

 

“Equipment Maturity Date” means
July 5, 2015.

 

“Term Loan A Interest-Only End Date”
means December 5, 2012.

 

Enumeral Biomedical Corp.
– 1st Amendment to LSA

 

    	2

    	 

    

 

“Term Loan A Maturity Date” means July 5, 2015.

 

“Term Loan B Availability End Date” means December 5,
2012.

 

“Term Loan B Interest-Only End Date” means December
5, 2012.

 

“Term Loan B Maturity Date” means July 5, 2015.

 

	 	5)	Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement.

 

	 	6)	Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment.

 

	 	7)	This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

 

	 	8)	As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:

 

a)          this Amendment, duly executed by Borrower;

 

b)          an
officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution and
delivery of this Amendment;

 

c)          a Second Warrant to Purchase Stock, duly executed by Borrower;

 

d)          payment
of a $5,500 facility fee, which may be debited from any of Borrower’s accounts;

 

e)          payment of all Bank Expenses, including Bank’s expenses
for the documentation of this Amendment and any related documents, and any UCC, good standing and intellectual property search
or filing fees, which may be debited from any of Borrower’s accounts; and

 

f)         such other
documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate.

 

[Signature Page Follows]

 

Enumeral Biomedical Corp.
– 1st Amendment to LSA

 

    	3

    	 

    

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment
        as of the first date above written.

 

	ENUMERAL BIOMEDICAL CORP.	 	SQUARE 1 BANK
	 	 	 
	By:	/s/ John J. Rydzewski	 	By:	/s/ Zack Robbins
	Name:	John J. Rydzewski	 	Name:	 Zack Robbins
	Title:	Executive Chairman 	 	Title:	AVP

 

[Signature Page to First Amendment to Loan and Security Agreement]

 

Enumeral Biomedical Corp.
– 1st Amendment to LSA

 

    	4

    	 

    

 

SECOND AMENDMENT

TO 

LOAN AND SECURITY
AGREEMENT

 

This Second Amendment to Loan and Security
Agreement (the “Amendment”), is made and entered into as of August 9, 2013, by and between SQUARE 1
BANK (the “Bank”) and ENUMERAL BIOMEDICAL CORP. (the “Borrower”).

 

RECITALS

 

Borrower and Bank are parties to that Loan and Security Agreement
dated as of December 5, 2011 (as amended from time to time, the “Agreement”). The parties desire to amend
the Agreement in accordance with the terms of this Amendment.

 

NOW, THEREFORE, the parties agree as follows:

 

		1)	Section 6.7 of the Agreement is hereby amended and restated, as follows:

 

6.7          Financial
Covenants. Borrower shall at all times maintain at least one of the following financial ratios and covenants;
provided, however, that from August 9, 2013 through the remainder of the 2013 calendar year, Borrower shall not be required to
maintain any of the financial ratios and covenants set forth in this Section 6.7:

 

(a)          Liquidity
Ratio. A Liquidity Ratio of at least 1.25 to 1.00; or

 

(b)          Cash
Burn. Tested monthly and calculated on a trailing six-months average, a Cash Bum of not more than the amounts shown in
column B below for the corresponding reporting period in column A.

 

	A	 	B	 
	Reporting Period Ending On	 	 	Maximum
                                         Cash Burn	 
	January 31, 2013	 	$	1,807,516	 
	February 28, 2013	 	$	1,917,511	 
	March 31, 2013	 	$	1,826,044	 
	April 30, 2013	 	$	1,700,391	 
	May 31, 2013	 	$	1,551,829	 
	June 30, 2013	 	$	1,646,901	 
	July 31, 2013	 	$	1,618,389	 
	August 31, 2013	 	$	1,574,255	 
	September 30, 2013	 	$	1,695,620	 
	October 31, 2013	 	$	1,762,491	 
	November 30, 2013	 	$	1,835,388	 
	December 31, 2013	 	$	2,000,835	 

 

Enumeral Biomedical Corp. – 2nd Amendment to
LSA Execution1

 

    	1

    	 

    

 

Bank and Borrower hereby agree that, on or before December 15th
of each year during the term of this Agreement, Borrower shall provide to Bank a fully-funded budget for the upcoming calendar
year, and Bank shall use that budget to establish the maximum Cash Bum amounts for the upcoming year, with such maximum amounts
being incorporated herein by an amendment, which shall be promptly executed by Bank and Borrower.

 

	 	2)	The following new Section 6.10 is hereby added to the Agreement, as follows:

 

6.10        Milestone
Covenants. Borrower shall achieve each; of the following milestones:

 

(a)          Minimum
Equity Milestone. On or before October 31, 2013, Borrower shall have received net Cash proceeds from the sale or issuance of
Borrower’s equity securities in an amount not less than $750,000 (the “Initial Equity Event”).

 

(b)          Term
Sheet Milestone. On or before December 31, 2013, Borrower’s receipt of a signed and accepted term sheet from one or more
investor(s) acceptable to Bank for the sale or issuance of Borrower’s equity securities on terms and conditions which shall
result in net Cash proceeds in amount not less than $2,500,000 (the “Term Sheet”); provided, however, the net Cash
proceeds required under the Term Sheet shall be reduced by: (i) Cash proceeds which are in excess of the required Cash amount pursuant
the Initial Equity Event, and (ii) funds to be received in the 2014 calendar year pursuant to signed term sheets, signed proposals
or signed contracts for new or expansion of existing partnership(s) or collaboration(s) that are also included in Borrower’s
2014 Board approved plan to be in effect beginning January 1, 2014; provided, further, that Borrower’s 2014 Board approved
plan evidences Borrower’s ability to retain a Cash balance throughout the remainder of the 2014 calendar year.

 

	 	3)	Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement.

 

	 	4)	Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment.

 

	 	5)	This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

 

	 	6)	As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:

 

b)          this Amendment, duly executed by Borrower;

 

Enumeral Biomedical Corp. – 2nd Amendment to
LSA Execution2

 

    	2

    	 

    

 

c)          payment of all Bank Expenses, including Bank’s expenses
for the documentation of this Amendment and any related documents, and any UCC, good standing and intellectual property search
or filing fees, which may be debited from any of Borrower’s accounts; and

 

b)          such other documents and completion of such other matters,
as Bank may reasonably deem necessary or appropriate.

 

[Signature Page Follows]

 

Enumeral Biomedical Corp. – 2nd Amendment to
LSA Execution3

 

    	3

    	 

    

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment
as of the first date above written.

 

	ENUMERAL BIOMEDICAL CORP.	 	SQUARE 1 BANK
	 	 	 	 	 
	By:	/s/ Derek Brand	 	By:	/s/ Zack Robbins
	Name:	Derek Brand	 	Name:	Zack Robbins
	Title:	VP Business Development & Finance	 	Title:	AVP

 

[Signature Page to Second Amendment to Loan and Security Agreement]

 

Enumeral Biomedical Corp. – 2nd Amendment to
LSA Execution4

 

    	4

    	 

    

 

THIRD AMENDMENT

TO

LOAN AND SECURITY AGREEMENT

 

This Third Amendment to Loan and Security
Agreement (this “Amendment”), is made and entered into as of February 3, 2014, by and between SQUARE
1 BANK (“Bank”) and ENUMERAL BIOMEDICAL CORP. (“Borrower”).

 

RECITALS

 

Borrower and Bank are parties to that Loan
and Security Agreement dated as of December 5, 2011 (as amended from time to time, the “Agreement”).
The parties desire to amend the Agreement in accordance with the terms of this Amendment.

 

NOW, THEREFORE, the parties agree as follows:

 

		1)	Section 6.7 of the Agreement is hereby amended and restated, as follows:

 

6.7           Financial
Covenants. Borrower shall maintain the following financial covenants:

 

(a)          Remaining
Months Cash. Beginning on the date on which Borrower achieves Equity Milestone I and continuing at all times thereafter. Borrower
shall maintain Remaining Months Cash of at least 3.0. For the avoidance of doubt, Remaining Months Cash shall be tested on a daily
basis, using the Cash Burn level for the most recent trailing- three-month period for which reporting is available.

 

(b)          Term
Sheet Requirement for Forthcoming RMC Violation. Before Borrower’s Remaining Months Cash falls below 3.0 in violation
of Section 6.7(a) above, Borrower shall submit to Bank a signed term sheet for the issuance of Borrower's equity securities, with
net Cash proceeds from such sale or issuance of at least $2,000,000, and otherwise on terms and from investors acceptable to Bank.
Borrower shall receive such net Cash proceeds within 30 days after the signed term sheet is delivered to Bank. During the period
after Bank has received the signed term sheet but before Borrower receives the required net Cash proceeds, Borrower shall be required
to maintain Remaining Months Cash of at least 2.0 instead of the level required by Section 6.7(a) above.

 

		2)	Section 6.10 of the Agreement is hereby amended and restated, as follows:

 

6.10         Milestone
Covenants. Borrower shall achieve each of the following milestone covenants:

 

(a)          Equity
Milestone I. Borrower shall achieve Equity Milestone I.

 

(b)          Equity
Milestone II. Borrower shall achieve Equity Milestone II.

 

Enumeral Biomedical Corp.
– 3rd Amendment to LSA

 

    	1

    	 

    

 

		3)	Section 8.2(a) of the Agreement is hereby amended and restated, as follows:

 

(a)          If
Borrower fails to perform any obligation under Sections 6.2 (financial reporting), 6.4 (taxes), 6.5 (insurance), 6.6 (primary
accounts), 6.7 (financial covenants), or 6.10 (milestone covenants), or violates any of the covenants contained in Article 7 of
this Agreement; or

 

		4)	The following defined terms are hereby added to Exhibit A to the Agreement, as follows:

 

“Equity Milestone I” means Borrower’s
receipt, after February 1, 2014 but on or before March 31, 2014, of net Cash proceeds of at least $2,000,000 from the sale or issuance
of Borrower’s equity securities to investors acceptable to Bank, which acceptance will not be unreasonably withheld.

 

“Equity Milestone II” means Borrower's
receipt, after February 1, 2014 but on or before June 30, 2014, of net Cash proceeds of at least $4,000,000 from the sale or issuance
of Borrower’s equity securities to investors acceptable to Bank, which acceptance will not be unreasonably withheld.

 

“Remaining Months Cash” means (i)
unrestricted Cash at Bank, divided by (ii) the monthly average of trailing-three-months Cash Burn.

 

	 	5)	The following defined term in Exhibit A to the Agreement is hereby amended and restated, as follows:

 

“Cash Burn” means an amount equal
to the prior period’s ending Cash minus the current period’s ending Cash that has been adjusted for any changes to
Cash as a result of borrowings and repayments of borrowings, proceeds from the sale of equity for Cash and the exercise of stock
options or warrants for Cash, and paid-in-capital and minority interest.

 

	 	6)	The defined terms “Liquidity” and “Liquidity Ratio” and their respective definitions in Exhibit A to the Agreement are hereby deleted.

 

		7)	Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined
in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective
terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and
performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under
the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements
entered into in connection with the Agreement.

 

		8)	Borrower represents and warrants that the representations and warranties contained in the Agreement
are true and correct as of the date of this Amendment.

 

		9)	This Amendment may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one instrument.

 

	 	10)	As a condition to the effectiveness of
this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:

 

Enumeral Biomedical Corp. –
3rd Amendment to LSA

 

    	2

    	 

    

 

	a)	this Amendment, duly executed by Borrower;

 

	b)	evidence that Borrower has received at least $635,000 in net Cash proceeds from the sale or issuance of Borrower’s Subordinated Debt securities to investors acceptable to Bank;

 

	a)	a subordination agreement, duly executed by each of Harris & Harris Group, Inc., Allan Rothstein, John J. Rydzewski, Michael Weiss, Emanuele Ostuni, and Peter Green and acknowledged by Borrower;

 

	b)	payment of all Bank Expenses, including Bank’s expenses for the documentation of this Amendment and any related documents, and any UCC, good standing and intellectual property search or filing fees, which may be debited from any of Borrower’s accounts; and

 

	c)	such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate.

 

[Signature Page Follows]

 

Enumeral Biomedical Corp.
– 3rd Amendment to LSA

 

    	3

    	 

    

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment
as of the first date above written.

 

	ENUMERAL BIOMEDICAL CORP.	 	SQUARE 1 BANK
	 	 	 	 	 
	By:	/s/ Derek Brand	 	By:	/s/ Zack Robbins
	Name:	Derek Brand	 	Name:	Zack Robbins
	Title:	VP Business Development Director of Finance	 	Title:	AVP

 

[Signature Page to Third Amendment to Loan and Security Agreement]

 

Enumeral Biomedical Corp.
– 3rd Amendment to LSA

 

    	4

    	 

    

 

 

FOURTH AMENDMENT

TO

LOAN AND SECURITY AGREEMENT

 

This
Fourth Amendment to Loan and Security Agreement (this “Amendment”),
is made and entered into as of June 26, 2014, by and between SQUARE 1 BANK (“Bank”)
and ENUMERAL BIOMEDICAL CORP. (“Borrower”).

 

RECITALS

 

Borrower
and Bank are parties to that Loan and Security Agreement dated as of December 5, 2011 (as amended from time to time, the “Agreement”).
The parties desire to amend the Agreement in accordance with the terms of this
Amendment.

 

NOW,
THEREFORE, the parties agree as follows:

 

		1)	Bank hereby waives Borrower's violation of the Remaining Months
Cash covenant, as set forth in Section 6.7(a) of the Agreement (as in effect prior to this Amendment), for all the dates from June
12, 2014 through the date of this Amendment.

 

		2)	Section 6.7(a) of the Agreement is hereby amended and restated,
as follows:

 

(a)     Remaining
Months Cash. Beginning on August
1, 2014 and continuing at all times thereafter, Borrower shall maintain Remaining Months Cash of at least 3.0. For the avoidance
of doubt, Remaining Months Cash shall be tested on a daily basis, using the Cash Burn level for the most recent trailing-three-month
period for which reporting is available.

 

		3)	A new Section 6.7(c) is hereby added to the Agreement, as follows:

 

(c)     Minimum
Cash. From June 26, 2014 through August 1, 2014, a balance of unrestricted Cash at Bank
of not less than $300,000, monitored on a daily basis.

 

		4)	The following defined term set forth in Exhibit A to the Agreement
is hereby amended and restated, as follows:

 

“Equity
Milestone II” means Borrower’s receipt, after February 1, 2014 but on or before August 1, 2014, of net Cash proceeds
of at least $4,000,000 from the sale or issuance of Borrower's equity securities to investors acceptable to Bank, which acceptance
will not be unreasonably withheld.

 

		5)	Unless otherwise defined, all initially capitalized terms in
this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect
in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein,
the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right,
power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing
effectiveness of all agreements entered into in connection with the Agreement.

 

Enumeral
Biomedical Corp. – 4th Amendment to LSA

 

    	1

    	 

    

 

		6)	Borrower represents and warrants that the representations and
warranties contained in the Agreement are true and correct as of the date of this Amendment.

 

		7)	This Amendment may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one instrument.

 

		8)	As a condition to the effectiveness of this Amendment, Bank shall
have received, in form and substance satisfactory to Bank, the following:

 

		a)	this Amendment, duly executed by Borrower;

 

		b)	payment of a $500 facility fee, which may be debited from any
of Borrower’s accounts;

 

		a)	payment of all Bank Expenses, including Bank’s expenses
for the documentation of this Amendment and any related documents, and any UCC, good standing and intellectual property search
or filing fees, which may be debited from any of Borrower’s accounts; and

 

		b)	such other documents and completion of such other matters, as
Bank may reasonably deem necessary or appropriate.

 

[Signature
Page Follows]

 

Enumeral
Biomedical Corp. –
4th Amendment to LSA

 

    	2

    	 

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Amendment as of the first date above written.

 

	ENUMERAL BIOMEDICAL CORP.	 	SQUARE 1 BANK
	 	 	 	 	 
	By:	/s/ Derek Brand	 	By:	/s/
    John Orlando
	Name :
    	Derek Brand	 	Name:
    	John
    Orlando
	Title: 	VP of Business Development & Director, Finance	 	Title:
    	AVP

 

[Signature
Page to Fourth Amendment to Loan and Security Agreement]

 

Enumeral Biomedical
Corp. – 4th
Amendment to LSA

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]